Cd70 combination therapy

ABSTRACT

The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.

RELATED APPLICATIONS

This application is a Division of U.S. patent application Ser. No.16/719,220, filed on Dec. 18, 2019, which claims the benefit of priorityof Great Britain Patent Application Nos. 1820582.3, filed Dec. 18, 2018;1911007.1, filed Aug. 1, 2019; and 1917701.3, filed Dec. 4, 2019, thedisclosures of which are herby incorporated herein by reference in theirentireties.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ST.26 XML format and is hereby incorporatedby reference in its entirety. Said ST.26 XML copy, created on Jun. 13,2023, is named 198969.XML and is 7,957 bytes in size.

FIELD OF THE INVENTION

The present invention relates to combination therapies, particularlycombination therapies for the treatment of myeloid malignancy. Thecombination therapies are particularly useful for the treatment of acutemyeloid leukemia (AML). The combination therapies include an antibody orantigen binding fragment thereof that binds to CD70 and a BCL-2inhibitor, for example venetoclax or a pharmaceutically acceptable saltthereof. The combination therapies may further include an additionalanti-cancer agent, for example an agent used for the treatment of AMLsuch as azacitidine or decitabine.

BACKGROUND TO THE INVENTION

In recent years, the development of new cancer treatments has focussedon molecular targets, particularly proteins, implicated in cancerprogression. The list of molecular targets involved in tumour growth,invasion and metastasis continues to expand, and includes proteinsoverexpressed by tumour cells as well as targets associated with systemssupporting tumour growth such as the vasculature and immune system. Thenumber of therapeutic or anti-cancer agents designed to interact withthese molecular targets also continues to increase. A large number oftargeted cancer medicines are now approved for clinical use with manymore in the developmental pipeline.

CD70 has been identified as a molecular target of particular interestowing to its constitutive expression on many types of hematologicalmalignancies and solid carcinomas (Junker et al. (2005) J Urol.173:2150-3; Sloan et al. (2004) Am J Pathol. 164:315-23; Held-Feindt andMentlein (2002) Int J Cancer 98:352-6; Hishima et al. (2000) Am J SurgPathol. 24:742-6; Lens et al. (1999) Br J Haematol. 106:491-503;Boursalian et al. (2009) Adv Exp Med Biol. 647:108-119; Wajant H. (2016)Expert Opin Ther Targets 20(8):959-973). CD70 is a type II transmembraneglycoprotein belonging to the tumour necrosis factor (TNF) superfamily,which mediates its effects through binding to its cognate cell surfacereceptor, CD27. Both CD70 and CD27 are expressed by multiple cell typesof the immune system and the CD70-CD27 signalling pathway has beenimplicated in the regulation of several different aspects of the immuneresponse. This is reflected in the fact that CD70 overexpression occursin various auto-immune diseases including rheumatoid and psoriaticarthritis and lupus (Boursalian et al. (2009) Adv Exp Med Biol.647:108-119; Han et al. (2005) Lupus 14(8):598-606; Lee et al. (2007) JImmunol. 179(4):2609-2615; Oelke et al. (2004) Arthritis Rheum.50(6):1850-1860).

CD70 expression has been linked to poor prognosis for several cancersincluding B cell lymphoma, renal cell carcinoma and breast cancer(Bertrand et al. (2013) Genes Chromosomes Cancer 52(8):764-774;Jilaveanu et al. (2012) Hum Pathol. 43(9):1394-1399; Petrau et al.(2014) J Cancer 5(9):761-764). CD70 expression has also been found onmetastatic tissue in a high percentage of cases indicating a key rolefor this molecule in cancer progression (Jacobs et al. (2015) Oncotarget6(15):13462-13475). Constitutive expression of CD70 and its receptorCD27 on tumour cells of hematopoietic lineage has been linked to a roleof the CD70-CD27 signalling axis in directly regulating tumour cellproliferation and survival (Goto et al. (2012) Leuk Lymphoma53(8):1494-1500; Lens et al. (1999) Br J Haematol. 106(2); 491-503;Nilsson et al. (2005) Exp Hematol. 33(12):1500-1507; van Doom et al(2004) Cancer Res. 64(16):5578-5586).

Upregulated CD70 expression on tumours, particularly solid tumours thatdo not co-express CD27, also contributes to immunosuppression in thetumour microenvironment in a variety of ways. For example, CD70 bindingto CD27 on regulatory T cells has been shown to augment the frequency ofTregs, reduce tumour-specific T cells responses and promote tumourgrowth in mice (Claus et al. (2012) Cancer Res. 72(14):3664-3676).CD70-CD27 signalling can also dampen the immune response bytumour-induced apoptosis of T-lymphocytes, as demonstrated in renal cellcarcinoma, glioma and glioblastoma cells (Chahlavi et al. (2005) CancerRes. 65(12):5428-5438; Diegmann et al. (2006) Neoplasia 8(11):933-938);Wischusen et al. (2002) Cancer Res 62(9):2592-2599). Finally, CD70expression has also been linked to T cell exhaustion whereby thelymphocytes adopt a more differentiated phenotype and fail to kill thetumour cells (Wang et al. (2012) Cancer Res 72(23):6119-6129; Yang etal. (2014) Leukemia 28(9):1872-1884).

Given the importance of CD70 in cancer development, CD70 is anattractive target for anti-cancer therapy and antibodies targeting thiscell surface protein are in clinical development (Jacob et al. (2015)Pharmacol Ther. 155:1-10; Silence et al. (2014) mAbs 6(2):523-532).

SUMMARY OF INVENTION

The present invention is directed to combination therapies comprisingantibodies or antigen binding fragments thereof that bind to CD70. Asnoted above, the list of proteins implicated in tumour growth continuesto expand, and combination therapies that target two or more of theseproteins are becoming increasingly attractive as anti-cancer treatments.In the combination therapies of the invention, an antibody or antigenbinding fragment thereof that binds to CD70 is combined with a BCL-2inhibitor, for example venetoclax or a pharmaceutically acceptable saltthereof. Overexpression of BCL-2 in cancer cells confers resistance toapoptosis and therefore inhibition of this protein can promote tumourcell death. As explained elsewhere herein, venetoclax is an example of apotent, selective small-molecule inhibitor of the BCL-2 protein. Asreported herein, the combination of an antibody or antigen bindingfragment thereof that binds to CD70 and a BCL-2 inhibitor, for examplevenetoclax or a pharmaceutically acceptable salt thereof, provides aneffective therapy for the treatment of cancer, particularly myeloidmalignancies such as acute myeloid leukemia (AML).

In a first aspect, the present invention provides a combinationcomprising (i) an antibody or antigen binding fragment thereof thatbinds to CD70; and (ii) a BCL-2 inhibitor. In certain preferredembodiments, the BCL-2 inhibitor is Compound (I) as shown below or apharmaceutically acceptable salt thereof.

Compound (I) is also referred to herein as venetoclax.

In certain embodiments, the antibody or antigen binding fragment thatbinds to CD70 is selected from: (i) an antibody or antigen bindingfragment comprising a variable heavy chain domain (VH) and a variablelight chain domain (VL) comprising the heavy chain CDRs (HCDR3, HCDR2and HCDR1) and light chain CDRs (LCDR3, LCDR2 and LCDR1): HCDR3comprising or consisting of SEQ ID NO: 3; HCDR2 comprising or consistingof SEQ ID NO: 2; HCDR1 comprising or consisting of SEQ ID NO: 1; LCDR3comprising or consisting of SEQ ID NO: 7; LCDR2 comprising or consistingof SEQ ID NO: 6; and LCDR1 comprising or consisting of SEQ ID NO: 5;(ii) an antibody or antigen binding fragment comprising a VH domaincomprising an amino acid sequence at least 70%, at least 80%, at least90%, at least 95% identical to SEQ ID NO:4 and a VL domain comprising anamino acid sequence at least 70%, at least 80%, at least 90%, at least95% identical to SEQ ID NO:8; or (iii) ARGX-110. In certain embodiments,the antibody is an IgG, preferably an IgG1.

The CD70 antibody or antigen binding fragment of the combinations maypossess one or more effector functions. In certain embodiments, theantibody or antigen binding fragment has ADCC activity; and/or comprisesa defucosylated antibody domain; and/or has CDC activity; and/or hasADCP activity. In preferred embodiments, the CD70 antibody is ARGX-110.

In certain embodiments, the CD70 antigen binding fragment of thecombinations is independently selected from the group consisting of: anantibody light chain variable domain (VL); an antibody heavy chainvariable domain (VH); a single chain antibody (scFv); a F(ab′)2fragment; a Fab fragment; an Fd fragment; an Fv fragment; a one-armed(monovalent) antibody; diabodies, triabodies, tetrabodies or anyantigen-binding molecule formed by combination, assembly or conjugationof such antigen binding fragments.

In certain embodiments, the CD70 antibody or antigen binding fragmentthereof and the BCL-2 inhibitor are formulated as separate compositions.In certain embodiments, the CD70 antibody or antigen binding fragmentthereof and venetoclax or a pharmaceutically acceptable salt thereof areformulated as separate compositions.

The combinations of the invention may comprise one or more additionaltherapeutic agents, for example at least one additional anti-canceragent, preferably an agent for the treatment of a myeloid malignancy. Incertain embodiments, the additional anti-cancer agent is an agent forthe treatment of acute myeloid leukemia (AML). In preferred embodiments,the combinations comprise a hypomethylating agent, preferablyazacitidine or decitabine.

In a further aspect, the present invention provides combinationsaccording to the first aspect of the invention for use in therapy. Inparticular, the present invention provides combinations according to thefirst aspect of the invention for use in the treatment of a malignancy,preferably a myeloid malignancy, in a human subject. The presentinvention also provides a method for treating a malignancy, preferably amyeloid malignancy, in a human subject, said method comprisingadministering to the subject an effective amount of any of thecombinations according to the first aspect of the invention.

The present invention also provides an antibody or antigen bindingfragment thereof that binds to CD70 for use in the treatment of amalignancy, preferably a myeloid malignancy, in a human subject, whereinthe antibody molecule is administered in combination with a BCL-2inhibitor, preferably compound (I) or a pharmaceutically acceptable saltthereof. The present invention also provides a BCL-2 inhibitor,preferably compound (I) or a pharmaceutically acceptable salt thereof,for use in the treatment of a myeloid malignancy in a human subject,wherein the BCL-2 inhibitor, preferably compound (I) or thepharmaceutically acceptable salt thereof, is administered in combinationwith an antibody or antigen binding fragment thereof that binds to CD70.

The combinations of the invention are particularly advantageous becausethey exhibit synergistic efficacy. Preferably, therefore, in embodimentsof all aspects of the invention, the dose at which the CD70 antibody orantigen binding fragment thereof is administered and/or provided in thecombination, and the dose at which the BCL-2 inhibitor is administeredand/or provided in the combination, are each selected such that thecombination provides synergistic treatment.

In certain preferred embodiments of the combination of the invention,the CD70 antibody or antigen binding fragment thereof and the BCL-2inhibitor are each present in the combination in an amount sufficient toprovide synergistic cell killing when cultured with an AML cell lineselected from: NOMO-1, MOLM-13, NB4 and MV4-11.

Regarding the malignancies to be treated using combinations of theinvention, said malignancies may be newly-diagnosed myeloidmalignancies; relapsed or refractory myeloid malignancies; or myeloidmalignancies selected from: acute myeloid leukemia (AML);myelodysplastic syndromes (MDS); myeloproliferative neoplasms (MPN);chronic myeloid leukemia (CML); and chronic myelomonocytic leukemia(CMML). In particularly preferred embodiment, the combinations of theinvention are for the treatment of acute myeloid leukemia (AML).

In certain embodiments, the subject or patient treated in accordancewith the methods of the invention is a newly-diagnosed AML patient whois ineligible for standard intensive chemotherapy. The subject may be anewly-diagnosed AML patient aged 75 years or older or a newly-diagnosedAML patient having a comorbidity that precludes use of standardintensive chemotherapy.

In certain embodiments, the CD70 antibody or antigen binding fragmentthereof is administered at a dose in the range of 0.1-25 mg/kg,preferably 10 mg/kg. Alternatively or in addition, the BCL-2 inhibitor,preferably venetoclax or pharmaceutically acceptable salt thereof, maybe administered in a dose in the range 100 mg-600 mg. In preferredembodiments, the methods described herein comprise administering acombination additionally comprising azacitidine wherein the azacitidineis administered at a dose of 75 mg/m². In further preferred embodiments,the methods described herein comprise administering a combinationadditionally comprising decitabine wherein the decitabine isadministered at a dose of 20 mg/m².

In certain embodiments, the methods further comprise monitoring of thepatient's blast count. The patient's peripheral blood and/or bone marrowblast count may be reduced, for example reduced to less than 25%, forexample reduced to 5%, for example reduced to less than 5%, for examplereduced to minimal residual disease levels, for example reduced toundetectable levels. In certain embodiments, the bone marrow blast countis reduced to between 5% and 25% and the bone marrow blast percentage isreduced by more than 50% as compared to pretreatment.

In certain embodiments, the methods induce a partial response. Incertain embodiments, the methods induce a complete response, optionallywith platelet recovery and/or neutrophil recovery. The methods mayinduce transfusion independence of red blood cells or platelets, orboth, for 8 weeks or longer, 10 weeks or longer, 12 weeks or longer. Incertain embodiments, the methods reduce the mortality rate after a30-day period or after a 60-day period.

In certain embodiments, the methods increase survival. For example, themethods may increase survival relative to the standard of care agent oragents used to treat the particular myeloid malignancy being treatedwith the combination. The methods may induce a minimal residual diseasestatus that is negative.

In certain embodiments, the methods further comprise a step ofsubjecting the subject to a bone marrow transplantation. Alternativelyor in addition, the methods may further comprise a step of administeringone or more additional anti-cancer agents. The one or more additionalcancer agents may be selected from any agents suitable for the treatmentof myeloid malignancies, preferably AML. Preferred agents may beselected from selectin inhibitors (e.g. GMI-1271); FMS-like tyrosinekinase receptor 3 (FLT3) inhibitors (e.g. midostaurin); cyclin-dependentkinase inhibitors; aminopeptidase inhibitors; JAK/STAT inhibitors;cytarabine; anthracycline compounds (e.g. daunorubicin, idarubicin);doxorubicin; hydroxyurea; Vyxeos; IDH1 or IDH2 inhibitors such as Idhifa(or Enasidenib) or Tibsovo (or ivosidenib); Smoothened inhibitors suchas Glasdegib, BET bromodomain inhibitors, CD123 or CD33 targetingagents, HDAC inhibitors, LSC targeting agents, AML bone marrow nichetargeting agents, and NEDD8-activating enzyme inhibitors such asPevonedistat.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 : Cusatuzumab and decitabine co-treatment synergisticallyeliminates NOMO-1 AML cells. NOMO-1 AML cells were treated with vehicle,cusatuzumab, venetoclax or decitabine alone or in combination in aconstant ratio in the presence of carboxyfluorescein succinimidyl ester(CFSE)-labeled NK cells (ratio 1:1). NOMO-1 AML cell numbers per wellwere counted after 72 hours, the degree of viable cells was determinedby Annexin V staining, and the effect of drug treatment was calculatedas the ratio of surviving cells to vehicle-treated cells. Combinationindex (CI) values were calculated, and values between 0 and 10 wereplotted against fraction affected (Fa) values. Fa-CI plot [Chou-Talalayplot] assessing synergism and/or antagonism is illustrated. Fa values of0, 0.5, and 1 correspond to 0, 50, and 100% killed cells. A CI of <1,1, >1 represents synergism, additivity, and antagonism, respectively.IC₅₀s indicates the Fa values reached at the IC₅₀ concentrations for theVe/Cusa (lower Fa) and Ve/De/Cusa (higher Fa) combinations. Ve/De,venetoclax and decitabine; De/Cusa, decitabine and cusatuzumab; Ve/Cusa,venetoclax and cusatuzumab; Ve/De/Cusa, venetoclax and decitabine andcusatuzumab.

FIGS. 2A-2D: Cusatuzumab and decitabine co-treatment synergisticallyeliminates NOMO-1 AML cells. Individual CI-Fa plots of the data for eachcombination presented in FIG. 1 . (FIG. 2A) venetoclax and decitabine;(FIG. 2B) decitabine and cusatuzumab; (FIG. 2C) venetoclax andcusatuzumab; (FIG. 2D) venetoclax, decitabine and cusatuzumab.

FIGS. 3A-3D: Cusatuzumab and decitabine co-treatment synergisticallyeliminates NB4 AML cells. NB4 AML cells were treated with vehicle,cusatuzumab, venetoclax or decitabine alone or in combination in aconstant ratio in the presence of CFSE-labeled NK cells (ratio 1:1). NB4AML cell numbers per well were counted after 72 hours, the degree ofviable cells was determined by Annexin V staining, and the effect ofdrug treatment was calculated as the ratio of surviving cells tovehicle-treated cells. Combination index (CI) values were calculated,and values between 0 and 10 were plotted against fraction affected (Fa)values. Fa-CI plot [Chou-Talalay plot] assessing synergism and/orantagonism is illustrated. Fa values of 0, 0.5, and 1 correspond to 0,50, and 100% killed cells. (FIG. 3A) venetoclax and decitabine; (FIG.3B) venetoclax and cusatuzumab; (FIG. 3C) decitabine and cusatuzumab;(FIG. 3D) venetoclax, decitabine and cusatuzumab.

FIGS. 4A-4D: Cusatuzumab and decitabine co-treatment synergisticallyeliminates MOLM-13 AML cells. MOLM-13 AML cells were treated withvehicle, cusatuzumab, venetoclax or decitabine alone or in combinationin a constant ratio in the presence of CFSE-labeled NK cells (ratio1:1). MOLM-13 AML cell numbers per well were counted after 72 hours, thedegree of viable cells was determined by Annexin V staining, and theeffect of drug treatment was calculated as the ratio of surviving cellsto vehicle-treated cells. Combination index (CI) values were calculated,and values plotted against fraction affected (Fa) values. Fa-CI plot[Chou-Talalay plot] assessing synergism and/or antagonism isillustrated. Fa values of 0, 0.5, and 1 correspond to 0, 50, and 100%killed cells. (FIG. 4A) venetoclax and decitabine; (FIG. 4B) venetoclaxand cusatuzumab; (FIG. 4C) decitabine and cusatuzumab; (FIG. 4D)venetoclax, decitabine and cusatuzumab.

FIG. 5 : Cusatuzumab and decitabine co-treatment synergisticallyeliminates MV4-11 AML cells. MV4-11 AML cells were treated with vehicle,cusatuzumab, venetoclax or decitabine alone or in combination in aconstant ratio in the presence of CFSE-labeled NK cells (ratio 1:1).MV4-11 AML cell numbers per well were counted after 72 hours, the degreeof viable cells was determined by Annexin V staining, and the effect ofdrug treatment was calculated as the ratio of surviving cells tovehicle-treated cells. Combination index (CI) values were calculated,and values plotted against fraction affected (Fa) values. Fa-CI plot[Chou-Talalay plot] assessing synergism and/or antagonism isillustrated. Fa values of 0, 0.5, and 1 correspond to 0, 50, and 100%killed cells.

FIGS. 6A-6B: Combined venetoclax and cusatuzumab treatmentsynergistically eliminates leukemic stem cells (LSCs) in vitro.CD34⁺CD38⁻ AML LSCs from patients P1-3 were cultured with cusatuzumab(Cusa: 0.3 μg/ml) or venetoclax (Ve: 6 nM) alone or in combination inthe presence of NK cells (ratio 1:1) overnight in duplicates followed byplating in methylcellulose. Colony formation was assessed 14 days later.(FIG. 6A) Absolute number of colonies per well for first platingfollowing treatment; (FIG. 6B) Cells harvested from the first platingwere re-plated (2^(nd) plating) and colonies per well assessed 14 dayslater. Data are represented as mean±S.D. Statistics: One-way-ANOVA;Tukey's post-test; *, P<0.05; **, P<0.01; ***, P<0.001.

FIGS. 7A-7B: Combined venetoclax and cusatuzumab treatmentsynergistically eliminates LSCs in vitro. Data presented correspond tothe data of FIG. 6 , normalized to the mean number of colonies per wellfollowing vehicle treatment for each patient. (FIG. 7A) first plating;(FIG. 7B) second plating.

FIGS. 8A-8B: Combined venetoclax and cusatuzumab treatmentsynergistically eliminates LSCs in vitro. CD34⁺CD38⁻ AML LSCs frompatients P4 and P5 were cultured with cusatuzumab (Cusa: 0.3 μg/ml),venetoclax (Ve: 6 nM) or decitabine (0.01 μM) alone or in combination inthe presence of NK cells (ratio 1:1) overnight in duplicates followed byplating in methylcellulose. Colony formation was assessed 14 days later.Data are represented as mean±S.D (FIG. 8A) Results from a singlepatient; (FIG. 8B) Results from P4 and P5.

FIG. 9 : CD70 mRNA expression (as percentage of housekeeping gene)following treatment with vehicle (Veh) or venetoclax (Ven) for 24 or 48hrs.

FIG. 10 : CD70 protein and mRNA expression by MOLM-13 and NOMO-1 cellsin the presence (gray bars) and absence (black bars) of venetoclax.Significance was determined using a Student's t-test. MFI=meanfluorescence intensity. *** P<0.001.

DETAILED DESCRIPTION A. Definitions

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as is commonly understood by one skilled in theart in the technical field of the invention.

“Combination therapy”—As used herein, the term “combination therapy”refers to a treatment in which a subject, for example a human subject,is given two or more therapeutic agents. The “combinations” describedherein are for use in combination therapy. The two or more therapeuticagents are typically administered so as to treat a single disease,herein a cancer or malignancy. The combinations or combination therapiesof the present invention comprise antibodies or antigen bindingfragments that bind to CD70 and a BCL-2 inhibitor, preferably thesmall-molecule inhibitor venetoclax or a pharmaceutically acceptablesalt thereof. As described elsewhere herein, the agents included in thecombination therapies may be co-formulated for administration or may beprovided separately, for example as separate compositions, foradministration to a subject or patient in need thereof.

“Antibody”—As used herein, the term “antibody” is intended to encompassfull-length antibodies and variants thereof, including but not limitedto modified antibodies, humanised antibodies, germlined antibodies. Theterm “antibody” is typically used herein to refer to immunoglobulinpolypeptides having a combination of two heavy and two light chainswherein the polypeptide has significant specific immunoreactive activityto an antigen of interest (herein CD70). For antibodies of the IgGclass, the antibodies comprise two identical light polypeptide chains ofmolecular weight approximately 23,000 Daltons, and two identical heavychains of molecular weight 53,000-70,000. The four chains are joined bydisulfide bonds in a “Y” configuration wherein the light chains bracketthe heavy chains starting at the mouth of the “Y” and continuing throughthe variable region. The light chains of an antibody are classified aseither kappa or lambda (κ,λ). Each heavy chain class may be bound witheither a kappa or lambda light chain. In general, the light and heavychains are covalently bonded to each other, and the “tail” portions ofthe two heavy chains are bonded to each other by covalent disulfidelinkages or non-covalent linkages when the immunoglobulins are generatedeither by hybridomas, B cells or genetically engineered host cells. Inthe heavy chain, the amino acid sequences run from an N-terminus at theforked ends of the Y configuration to the C-terminus at the bottom ofeach chain.

Those skilled in the art will appreciate that heavy chains areclassified as gamma, mu, alpha, delta, or epsilon, (γ, μ, α, δ, ε) withsome subclasses among them (e.g., γ1-γ4). It is the nature of this chainthat determines the “class” of the antibody as IgG, IgM, IgA, IgD orIgE, respectively. The immunoglobulin subclasses (isotypes) e.g., IgG1,IgG2, IgG3, IgG4, IgA1, etc. are well characterized and are known toconfer functional specialization. The term “antibody” as used hereinencompasses antibodies from any class or subclass of antibody.

“Antigen binding fragment”—The term “antigen binding fragment” as usedherein refers to fragments that are parts or portions of a full-lengthantibody or antibody chain comprising fewer amino acid residues than anintact or complete antibody whilst retaining antigen binding activity.An antigen-binding fragment of an antibody includes peptide fragmentsthat exhibit specific immuno-reactive activity to the same antigen asthe antibody (e.g. CD70). The term “antigen binding fragment” as usedherein is intended to encompass antibody fragments selected from: anantibody light chain variable domain (VL); an antibody heavy chainvariable domain (VH); a single chain antibody (scFv); a F(ab′)2fragment; a Fab fragment; an Fd fragment; an Fv fragment; a one-armed(monovalent) antibody; diabodies, triabodies, tetrabodies or anyantigen-binding molecule formed by combination, assembly or conjugationof such antigen binding fragments. The term “antigen binding fragment”as used herein may also encompass antibody fragments selected from thegroup consisting of: unibodies; domain antibodies; and nanobodies.Fragments can be obtained, for example, via chemical or enzymatictreatment of an intact or complete antibody or antibody chain or byrecombinant means.

“Specificity” and “Multispecific antibodies”—The antibodies and antigenbinding fragments for use in the combination therapies described hereinbind to particular target antigens, e.g. CD70. It is preferred that theantibodies and antigen binding fragments “specifically bind” to theirtarget antigen, wherein the term “specifically bind” refers to theability of any antibody or antigen binding fragment to preferentiallyimmunoreact with a given target e.g. CD70. The antibodies and antigenbinding fragments of the present combinations and methods may bemonospecific and contain one or more binding sites which specificallybind a particular target. The antibodies and antigen binding fragmentsof the present combinations and methods may be incorporated into“multispecific antibody” formats, for example bispecific antibodies,wherein the multispecific antibody binds to two or more target antigens.In order to achieve multiple specificities, “multispecific antibodies”are typically engineered to include different combinations or pairingsof heavy and light chain polypeptides with different VH-VL pairs.Multispecific, notably bispecific antibodies, may be engineered so as toadopt the overall conformation of a native antibody, for example aY-shaped antibody having Fab arms of different specificities conjugatedto an Fc region. Alternatively multispecific antibodies, for examplebispecific antibodies, may be engineered so as to adopt a non-nativeconformation, for example wherein the variable domains or variabledomain pairs having different specificities are positioned at oppositeends of the Fc region.

“Modified antibody”—As used herein, the term “modified antibody”includes synthetic forms of antibodies which are altered such that theyare not naturally occurring, e.g., antibodies that comprise at least twoheavy chain portions but not two complete heavy chains (such as, domaindeleted antibodies or minibodies); multispecific forms of antibodies(e.g., bispecific, trispecific, etc.) altered to bind to two or moredifferent antigens or to different epitopes on a single antigen); heavychain molecules joined to scFv molecules and the like. scFv moleculesare known in the art and are described, e.g., in U.S. Pat. No.5,892,019. In addition, the term “modified antibody” includesmultivalent forms of antibodies (e.g., trivalent, tetravalent, etc.,antibodies that bind to three or more copies of the same antigen). Inanother embodiment, a modified antibody of the invention is a fusionprotein comprising at least one heavy chain portion lacking a CH2 domainand comprising a binding domain of a polypeptide comprising the bindingportion of one member of a receptor ligand pair.

“Humanising substitutions”—As used herein, the term “humanisingsubstitutions” refers to amino acid substitutions in which the aminoacid residue present at a particular position in the VH or VL domain ofan antibody is replaced with an amino acid residue which occurs at anequivalent position in a reference human VH or VL domain. The referencehuman VH or VL domain may be a VH or VL domain encoded by the humangermline. Humanising substitutions may be made in the framework regionsand/or the CDRs of the antibodies, defined herein.

“Humanised variants”—As used herein the term “humanised variant” or“humanised antibody” refers to a variant antibody which contains one ormore “humanising substitutions” compared to a reference antibody,wherein a portion of the reference antibody (e.g. the VH domain and/orthe VL domain or parts thereof containing at least one CDR) has an aminoacid derived from a non-human species, and the “humanisingsubstitutions” occur within the amino acid sequence derived from anon-human species.

“Germlined variants”—The term “germlined variant” or “germlinedantibody” is used herein to refer specifically to “humanised variants”in which the “humanising substitutions” result in replacement of one ormore amino acid residues present at (a) particular position(s) in the VHor VL domain of an antibody with an amino acid residue which occurs atan equivalent position in a reference human VH or VL domain encoded bythe human germline. It is typical that for any given “germlinedvariant”, the replacement amino acid residues substituted into thegermlined variant are taken exclusively, or predominantly, from a singlehuman germline-encoded VH or VL domain. The terms “humanised variant”and “germlined variant” are often used interchangeably. Introduction ofone or more “humanising substitutions” into a camelid-derived (e.g.llama derived) VH or VL domain results in production of a “humanisedvariant” of the camelid (llama)-derived VH or VL domain. If the aminoacid residues substituted in are derived predominantly or exclusivelyfrom a single human germline-encoded VH or VL domain sequence, then theresult may be a “human germlined variant” of the camelid (llama)-derivedVH or VL domain.

“CD70”—As used herein, the terms “CD70” or “CD70 protein” or “CD70antigen” are used interchangeably and refer to a member of the TNFligand family which is a ligand for TNFRSF7/CD27. CD70 is also known asCD27L or TNFSF7. The terms “human CD70 protein” or “human CD70 antigen”or “human CD70” are used interchangeably to refer specifically to thehuman homolog, including the native human CD70 protein naturallyexpressed in the human body and/or on the surface of cultured human celllines, as well as recombinant forms and fragments thereof. Specificexamples of human CD70 include the polypeptide having the amino acidsequence shown under NCBI Reference Sequence Accession No. NP_001243, orthe extracellular domain thereof.

“BCL-2 family”—As used herein, the term “BCL-2 family” or “BCL-2 proteinfamily” refers to the collection of pro- and anti-apoptotic proteinsrelated to BCL-2, see Delbridge et al. (2016) Nat Rev Cancer. 16(2):99-109. There are at least 16 members of this family categorized intothree functional groups: (i) the BCL-2 like proteins (e.g. BCL-2,BCL-X_(L/)BCL2L1, BCLW BCL2L2, MCL2, BFL1/BCL2A1); (ii) BAX and BAK; and(iii) the BH3-only proteins (e.g. BIM, PUMA, BAD, BMF, BID, NOXA, HRK,BIK). The BCL-2 family of proteins play an integral role in regulatingthe intrinsic apoptotic pathway with the anti-apoptotic members of thefamily (e.g. BCL-2, BCL-X_(L)) typically antagonizing the pro-apoptoticmembers (e.g. BAX and BIM). Deregulation of BCL-2 family members hasbeen observed in many cancers, for example by gene translocations,amplifications, overexpression and mutations. The downstream effect ofthis deregulation is frequently apoptosis-resistance, which fuels cancergrowth.

“BCL-2”—As used herein, “BCL-2” or the “BCL-2 protein” refers to thefirst member of the BCL-2 protein family to be identified in humans i.e.B-cell lymphoma 2. The cDNA encoding human BCL-2 was cloned in 1986 andthe key role of this protein in inhibiting apoptosis was elucidated in1988. BCL-2 has been found to be upregulated in several different typesof cancer. For example, BCL-2 is activated by the t(14;18) chromosomaltranslocation in follicular lymphoma. Amplification of the BCL-2 genehas also been reported in different cancers including leukemias (such asCLL), lymphomas (such as B-cell lymphoma) and some solid tumours (e.g.small-cell lung carcinoma). Human BCL-2 is encoded by the BCL2 gene(UniProtKB—P10415) and has the amino acid sequences shown under NCBIReference Sequences NP_000624.2 and NP_000648.2.

“BCL-2 inhibitor”—As used herein, a BCL-2 inhibitor refers to any agent,compound or molecule capable of specifically inhibiting the activity ofBCL-2, in particular an agent, compound or molecule capable ofinhibiting the anti-apoptotic activity of BCL-2. Examples of BCL-2inhibitors suitable for use in the combinations described herein includeB cell lymphoma homology 3 (BH3) mimetic compounds (Merino et al. (2018)Cancer Cell. 34(6): 879-891). Particular BCL-2 inhibitors include butare not limited to venetoclax, ABT-737 (Oltersdorf, T. et al. (2005)Nature 435: 677-681), navitoclax/ABT-263 (Tse, C. et al. (2008) CancerRes. 68: 3421-3428), BM-1197 (Bai, L. et al. (2014) PLoS ONE 9: e99404),S44563 (Nemati, F. et al. (2014) PLoS ONE 9: e80836), BCL2-32 (Adam, A.et al. (2014) Blood 124: 5304), AZD4320 (Hennessy, E. J. et al. (2015)ACS Medicinal Chemistry annual meetinghttps://www.acsmedchem.org/ama/orig/abstracts/mediabstractf2015.pdf_abstr.24),and S55746 (International Standard Randomised Controlled Trial NumberRegistry. ISRCTN http://www.isrctn.com/ISRCTN04804337 (2016). Furtherexamples of BCL-2 inhibitors are described in Ashkenazi, A et al. (2017)Nature Reviews Drug Discovery 16: 273-284, incorporated herein byreference.

“Venetoclax”—As used herein, the term “venetoclax” refers to thecompound having the chemical structure shown below:

This compound is referred to herein as “compound (I)”. Venetoclax is apotent, selective, orally-bioavailable inhibitor of the BCL-2 protein.It has the empirical formula C₄₅H₅₀ClN₇O₇S and a molecular weight of868.44. It has very low aqueous solubility. Venetoclax can be describedchemically as4-(4-{[2-(4-chlorophenyl)-4,4dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide).Alternative names for venetoclax include ABT-199; chemical name1257044-40-8; GDC-0199.

Venetoclax received approval in 2015 from the US Food and DrugAdminstration (FDA) for the treatment of adult patients with chroniclymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who havereceived at least one prior therapy. Venetoclax is also approved in theUS for use in combination with azacitidine or decitabine or low-dosecytarabine for the treatment of newly-diagnosed acute myeloid leukemia(AML) in adults aged 75 years or older or who have comorbidities thatpreclude use of intensive induction chemotherapy.

“Myeloid malignancy”—As used herein, the term “myeloid malignancy”refers to any clonal disease of hematopoietic stem or progenitor cells.Myeloid malignancies or myeloid malignant diseases include chronic andacute conditions. Chronic conditions include myelodysplastic syndromes(MDS), myeloproliferative neoplasms (MPN) and chronic myelomonocyticleukemia (CMML), and acute conditions include acute myeloid leukemia(AML).

“Acute myeloid malignancy”—As used herein, “acute myeloid leukemia” or“AML” refers to haematopoietic neoplasms involving myeloid cells. AML ischaracterised by clonal proliferation of myeloid precursors with reduceddifferentiation capacity. AML patients exhibit an accumulation of blastcells in the bone marrow. “Blast cells”, or simply “blasts”, as usedherein refers to clonal myeloid progenitor cells exhibiting disrupteddifferentiation potential. Blast cells typically also accumulate in theperipheral blood of AML patients. Typically AML is diagnosed if thepatient exhibits 20% or more blast cells in the bone marrow orperipheral blood.

“Standard intensive chemotherapy”—As used herein, “standard intensivechemotherapy” (also referred to herein as “intensive induction therapy”or “induction therapy”) refers to the so-called “7+3” inductionchemotherapy characterised by 7 days of high dose cytarabine followed by3 days of anthracycline administration (e.g. daunorubicin oridarubicin). Standard intensive chemotherapy can be given to eligiblenewly-diagnosed AML patients with the aim of inducing complete remissionof AML, typically with the intention of the patient undergoing a stemcell transplant following successful chemotherapy. As explained herein,not all newly-diagnosed AML patients are eligible for this standardintensive chemotherapy.

“Leukemic stem cells”—As used herein, “leukemic stem cells” or “LSCs”are a subset of the blast cells associated with AML. LSCs are blastcells having stem cell properties such that, if transplanted into animmuno-deficient recipient, they are capable of initiating leukemicdisease. LSCs can self-renew by giving rise to leukemia and alsopartially differentiate into non-LSC conventional blast cells thatresemble the original disease but are unable to self-renew. LSCs occurwith a frequency in the range of 1 in 10,000 to 1 in 1 million as aproportion of primary AML blast cells (Pollyea and Jordan (2017) Blood129: 1627-1635, incorporated herein by reference). LSCs may becharacterised as cells that are CD34+, CD38−, optionally also CD45−and/or CD123+. LSCs may also be characterised as CD45dim, SSClo,CD90+CD34+ cells.

“Anti-cancer agent”—As used herein, an anti-cancer agent refers to anyagent that is capable of preventing, inhibiting or treating cancergrowth directly or indirectly. Such agents include chemotherapeuticagents, immunotherapeutic agents, anti-angiogenic agents, radionuclides,etc, many examples of which are known to those skilled in the art.

B. Combination Therapy with a CD70 Antibody and a BCL-2 Inhibitor

The present invention provides a combination therapy comprising (i) anantibody or antigen binding fragment thereof that binds to CD70; and(ii) a BCL-2 inhibitor.

As described elsewhere herein, CD70 has already been characterised as anattractive target for anti-cancer therapy. CD70 is constitutivelyexpressed on many types of hematological malignancies and solidcarcinomas and its expression has been linked to poor prognosis forseveral cancers. Antibodies targeting CD70 have been developed and somehave been taken forward into clinical development.

Antibodies targeting CD70 have been found to be particularly effectivefor the treatment of myeloid malignancies, particularly the treatment ofsubjects with acute myeloid leukemia (AML). The results from a PhaseI/II clinical trial testing the CD70 antibody, ARGX-110, in patientshaving AML revealed surprising efficacy in this indication, particularlyin newly-diagnosed patients classified as unfit for standard intensivechemotherapy (see WO2018/229303). It is particularly notable that in theclinical studies, the CD70 antibody, when used in combination withazacitidine, efficiently reduced leukemic stem cells (LSCs) in the AMLpatients. Testing of the LSCs isolated from the patients in the trialrevealed evidence of increased asymmetric division of LSCs, indicativeof differentiation into myeloid cells. Taken together, these resultsindicate that CD70 antibodies deplete the LSC pool in AML patientsthereby increasing the prospect of remission and reducing the risk ofrelapse.

The present invention combines CD70 antibodies or antigen bindingfragments thereof with a BCL-2 inhibitor.

The BCL-2 protein is a member of the BCL-2 family. This family comprisesmore than 20 proteins. Members of the BCL-2 family are involved in theregulation of the intrinsic apoptosis pathway and play a fundamentalrole in regulating the balance between cell survival and death.

The BCL-2 protein is an anti-apoptotic member of the BCL-2 family and isup-regulated in many different types of cancer. The overexpression ofBCL-2 allows tumour cells to evade apoptosis by sequesteringpro-apoptotic proteins. BCL-2 is highly expressed in many hematologicmalignancies and is the predominant pro-survival protein in diseasessuch as chronic lymphocytic leukemia (CLL), follicular lymphoma andmantle cell lymphoma. Inhibition of BCL-2 inhibits the anti-apoptotic orpro-survival activity of this protein. Anti-apoptotic members of theBCL-2 family, including BCL-2, have been reported as overexpressed inprimary AML samples (Bogenberger et al. (2014) Leukemia 28(2); 1657-65).BCL-2 overexpression has also been reported in leukemic stem cells(LSCs) obtained from AML patients (Lagadinou et al. (2013) Cell StemCell 12(3); 329-341). Inhibition of BCL-2 in ex vivo LSC populations ledto selective eradication of quiescent LSCs (Lagadinou et al. (2013) CellStem Cell 12(3); 329-341).

Without wishing to be bound by theory, the combination of the presentinvention is considered to be particularly effective for the treatmentof AML due to the combined therapeutic effect of the CD70 antibodies orantigen binding fragments and the BCL-2 inhibitor, particularly thecombined effect at the level of the LSCs. The self-renewal capacity ofLSCs means that the persistence of these cells is a major factorcontributing to disease relapse.

As demonstrated in the Examples, combinations of the invention exhibitsynergistic treatment efficacy against AML cells—that is, the level ofinhibition induced by the combination is greater than the additiveeffect of the monotherapies alone. Methods for determining synergisticinteraction are familiar to the skilled person and are described in theExamples. A preferred method for determining whether synergistic effectsarise from a combination is the Chou-Talalay method (Chou, TC. CancerRes. (2010) 70(2); 440-6, incorporated herein by reference).

The synergistic efficacy of the combinations of the invention translatedinto potent inhibition of primary LSC cells from AML patients. Thecombination therapy of the present invention thus targets both the blastcells and the LSC compartment thereby improving the likelihood ofdisease remission whilst reducing the risk of relapse.

In certain preferred embodiments of the combinations of the invention,the BCL-2 inhibitor is venetoclax or a pharmaceutically acceptable saltthereof. Venetoclax is a small-molecule inhibitor of BCL-2, described inUS2010/0305122 (incorporated herein by reference).

By inhibiting BCL-2, venetoclax inhibits the anti-apoptotic orpro-survival activity of this protein. Venetoclax induces apoptosisrapidly in the majority of CLL cells and BCL-2-overexpressing lymphomacell lines.

Early studies indicated that venetoclax may be useful as a therapy forAML (Konopleva et al. (2016) Cancer Discov. 6(10); 1106-17). However, itwas found to have limited activity as a monotherapy. Subsequent studiesinvestigated the efficacy of venetoclax in combination withhypomethylating agents, namely azacitidine and decitadine, and thesecombinations were found to be particularly efficacious (Bogenberger etal. (2015) Leuk Lymphoma 56(1): 226-229). Clinical trials have beencarried out to test the combination of venetoclax with eitherazacitidine, decitabine, or low-dose cytarabine (Dinardo et al. (2018)Lancet Oncol. 19(2): 216-228; Dinardo et al. (2019) Blood 133(1); 7-17).The results of these trials have led to FDA approval for use ofvenetoclax in combination with azacitidine, decitabine or low-dosecytarabine for the treatment of newly-diagnosed acute myeloid leukemia(AML) in adults who are age 75 years or older, or who have comorbiditiesthat preclude the use of intensive induction chemotherapy.

In certain alternative embodiments of the invention, the BCL-2 inhibitoris a B cell lymphoma homology 3 (BH3) mimetic compound. In certainembodiments, the BCL-2 inhibitor is selected from ABT-737, navitoclax,BM-1197, S44563, BCL2-32, AZD4320 or S55746.

CD70 Antibodies

Antibodies or antigen binding fragments that bind to CD70 and that maybe incorporated into any of the combinations described herein includebut are not limited to: CD70 antibodies or antigen binding fragmentsthat inhibit interaction of CD70 with CD27; CD70 antibodies or antigenbinding fragments that compete with CD27 for CD70 binding; CD70antibodies or antigen binding fragments that inhibit CD70-induced CD27signalling; CD70 antibodies or antigen binding fragments that inhibitTreg activation and/or proliferation; CD70 antibodies or antigen bindingfragments that deplete CD70-expressing cells; CD70 antibodies or antigenbinding fragments that induce lysis of CD70-expressing cells; CD70antibodies or antigen binding fragments that possess ADCC, CDCfunctionality, and/or induce ADCP.

Exemplary CD70 antibodies are ARGX-110 described in WO2012/123586(incorporated herein by reference), SGN-70 (WO2006/113909, andMcEarChern et al. (2008) Clin Cancer Res. 14(23):7763, both incorporatedherein by reference) and those CD70 antibodies described inWO2006/044643 and WO2007/038637 (each incorporated herein by reference).

WO2006/044643 describes CD70 antibodies containing an antibody effectordomain which can mediate one or more of ADCC, ADCP or CDC and eitherexert a cytostatic or cytotoxic effect on a CD70-expressing cancer orexert an immunosuppressive effect on a CD70-expressing immunologicaldisorder in the absence of conjugation to a cytostatic or cytotoxicagent. The antibodies exemplified therein are based on theantigen-binding regions of two monoclonal antibodies, denoted 1F6 and2F2.

WO2007/038637 describes fully human monoclonal antibodies that bind toCD70. These antibodies are characterised by binding to human CD70 with aK_(D) of 1×10⁷ M or less. The antibodies also bind to, and areinternalised by, renal cell carcinoma tumor cell lines which expressCD70, such as 786-0.

ARGX-110 is an IgG1 anti-CD70 antibody, also known as cusatuzumab.ARGX-110 has been shown to inhibit the interaction of CD70 with itsreceptor CD27 (Silence et al. (2014) MAbs. March-April; 6(2):523-32,incorporated herein by reference). In particular, ARGX-110 has beenshown to inhibit CD70-induced CD27 signalling. Levels of CD27 signallingmay be determined by, for example, measurement of serum soluble CD27 asdescribed in Riether et al. (J. Exp. Med. (2017) 214(2); 359-380) or ofIL-8 expression as described in Silence et al. (MAbs (2014) 6(2):523-32). Without being bound by theory, inhibiting CD27 signalling isthought to reduce activation and/or proliferation of Treg cells, therebyreducing inhibition of anti-tumour effector T cells. ARGX-110 has alsobeen demonstrated to deplete CD70-expressing tumour cells. Inparticular, ARGX-110 has been shown to lyse CD70-expressing tumour cellsvia antibody dependent cell-mediated cytotoxicity (ADCC) and complementdependent cytotoxicity (CDC), and also to increase antibody dependentcellular phagocytosis (ADCP) of CD70-expressing cells (Silence et al.,ibid).

The CDR, VH and VL amino acid sequences of ARGX-110 or cusatuzumab areshown in the table below.

TABLE 1 ARGX-110 Sequence SEQ ID NO. HCDR1 VYYMN 1 HCDR2DINNEGGTTYYADSVKG 2 HCDR3 DAGYSNHVPIFDS 3 VH EVQLVESGGGLVQPGGSLRLSCAAS 4GFTFSVYYMNWVRQAPGKGLEWVSD INNEGGTTYYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAVYYCARDA GYSNHVPIFDSWGQGT LVTVSS LCDR1 GLKSGSVTSDNFPT 5LCDR2 NTNTRHS 6 LCDR3 ALFISNPSVE 7 VL QAVVTQEPSLTVSPGGTVTLTCGLK 8SGSVTSDNFPTWYQQTPGQAPRLLI YNTNTRHSGVPDRFSGSILGNKAALTITGAQADDEAEYFCALFISNPSVE FGGGTQLTVLG

In certain embodiments, the antibody or antigen binding fragment thereofthat binds to CD70 comprises a variable heavy chain domain (VH) and avariable light chain domain (VL) wherein the VH and VL domains comprisethe CDR sequences:

-   -   HCDR3 comprising or consisting of SEQ ID NO: 3;    -   HCDR2 comprising or consisting of SEQ ID NO: 2;    -   HCDR1 comprising or consisting of SEQ ID NO: 1;    -   LCDR3 comprising or consisting of SEQ ID NO: 7;    -   LCDR2 comprising or consisting of SEQ ID NO: 6; and    -   LCDR1 comprising or consisting of SEQ ID NO: 5.

In certain embodiments, the antibody or antigen binding fragment thereofthat binds to CD70, optionally the antibody or antigen binding fragmenthaving the CDR sequences shown above, is an IgG, preferably an IgG1. Incertain embodiments, the antibody or antigen binding fragment thereofthat binds to CD70 comprises a variable heavy chain domain (VH domain)comprising or consisting of a sequence at least 70%, at least 80%, atleast 90% or at least 95% identical to SEQ ID NO: 4 and a variable lightchain domain (VL domain) comprising or consisting of a sequence at least70%, at least 80%, at least 90% or at least 95% identical to SEQ ID NO:8. In certain embodiments, the antibody molecule that binds to CD70comprises a variable heavy chain domain (VH domain) comprising orconsisting of SEQ ID NO: 4 and a variable light chain domain (VL domain)comprising or consisting of SEQ ID NO: 8. For embodiments wherein the VHand/or VL domains are defined as having a particularly percentageidentity to a reference sequence, the VH and/or VL domains may retainthe CDR sequences of the reference sequence. In particular, the CD70antibodies or antigen binding fragments defined herein with reference toSEQ ID NOs: 4 and 8 may retain the CDR sequences as represented by SEQID NOs: 1-3 and 5-7.

CD70 antibody or antigen binding fragments thereof that may beincorporated into the combinations described herein include antibodydrug conjugates (ADCs). ADCs are antibodies attached to active agents,for example auristatins and maytansines or other cytotoxic agents.Certain ADCs maintain antibody blocking and/or effector function (e.g.ADCC, CDC, ADCP) while also delivering the conjugated active agent tocells expressing the target (e.g. CD70). Examples of anti-CD70 ADCsinclude vorsetuzumab mafodotin (also known as SGN-75, Seattle Genetics),SGN-70A (Seattle Genetics), and MDX-1203/BMS936561 (Bristol-MyersSquibb), each of which may be used in accordance with the invention.Suitable anti-CD70 ADCs are also described in WO2008074004 andWO2004073656, each of which is incorporated herein by reference.

Venetoclax

In certain preferred embodiments of the invention, the CD70 antibodiesor antigen binding fragments described herein are combined withvenetoclax or a pharmaceutically acceptable salt thereof. Venetoclax isa small molecule inhibitor of BCL-2 as described elsewhere herein.

Venetoclax for use in the combination therapies described herein may beprovided in any suitable form such that it effectively inhibits theBCL-2 protein. Such forms include but are not limited to any suitablepolymorphic, amorphous or crystalline forms or any isomeric ortautomeric forms. In certain embodiments, the combination therapiesdescribed herein comprise venetoclax synthesised according to theprocess described in US2010/0305122 (incorporated herein by reference).In alternative embodiments, the combination therapies described hereincomprise venetoclax according to the forms or synthesised according tothe processes described in any one of EP3333167, WO2017/156398,WO2018/029711, CN107089981 (A), WO2018/069941, WO2017/212431,WO2018/009444, CN107648185 (A), WO2018/167652, WO2018/157803, CZ201769(each incorporated herein by reference). In certain embodiments, thecombination therapies described herein comprise venetoclax in any of thecrystalline or salt forms described in WO2012/071336 (incorporatedherein by reference).

Pharmaceutically acceptable salts for use in accordance with the presentinvention include salts of acidic or basic groups. Pharmaceuticallyacceptable acid addition salts include, but are not limited to,hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate,phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate,citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate,maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate,formate, benzoate, glutamate, methanesulfonate, ethanesulfonate,benzensulfonate, p-toluenesulfonate and pamoate (i.e.,1,1′-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Pharmaceuticallyacceptable salts may be formed with various amino acids. Suitable basesalts include, but are not limited to, aluminum, calcium, lithium,magnesium, potassium, sodium, zinc, and diethanolamine salts.

Venetoclax for use in the combination therapies described herein mayalso be provided in the form of a hydrate, anhydrate or solvate.

Venetoclax is marketed and sold by AbbVie Inc and Genentech under thetrade name Venclexta®. In certain embodiments, the combinationsdescribed herein comprise an antibody or antigen binding fragmentthereof that binds CD70 and Venclexta®.

Additional Agents

The combinations of the present invention may include one or moreadditional agents, for example one or more additional anti-canceragents.

In certain embodiments, the combination comprises one or more“nucleoside metabolic inhibitors” (NMIs). NMIs are molecules thatinterfere with epigenetic modification (e.g. methylation, demethylation,acetylation, or deacetylation) of nucleotides (DNA and/or RNA). Examplesof nucleoside metabolic inhibitors include hypomethylating agents(HMAs), isocitrate dehydrogenase (IDH) inhibitors, histone deacetylase(HDAC) inhibitors, and bromodomain and extraterminal (BET) inhibitors.Preferred nucleoside metabolic inhibitors are hypomethylating agents.Hypomethylating agents inhibit normal methylation of DNA and/or RNA.Examples of hypomethylating agents are azacitidine, decitabine andguadecitabine.

In preferred embodiments, the combinations of the invention additionallycomprise azacitidine (also referred to herein as azacytidine, AZA oraza). Thus, in preferred embodiments, the present invention provides acombination comprising (i) an antibody or antigen binding fragmentthereof that binds to CD70; (ii) venetoclax or a pharmaceuticallyacceptable salt thereof; and (iii) azacitidine.

In further preferred embodiments, the combinations of the inventionadditionally comprise decitabine. Thus, in preferred embodiments, thepresent invention provides a combination comprising (i) an antibody orantigen binding fragment thereof that binds to CD70; (ii) venetoclax ora pharmaceutically acceptable salt thereof; and (iii) decitabine.

Azacitidine is an analogue of cytidine and decitabine is its deoxyderivative. Azacitdine and decitabine are inhibitors of DNAmethyltransferases (DNMT) known to upregulate gene expression bypromoter hypomethylation. Such hypomethylation disrupts cell function,thereby resulting in cytotoxic effects.

In certain embodiments, the combinations of the present inventionadditionally comprise cytarabine. Cytarabine (also known as “cytosinearabinose” or “ara-C”) is a chemotherapeutic drug commonly used to treatAML. High-dose cytarabine forms part of the “7+3” standard inductionchemotherapy typically used for newly-diagnosed AML patients. Low-dosecytarabine may be used for AML patients who are not eligible for thestandard induction chemotherapy. For example, low-dose cytarabine isprescribed in combination with venetoclax for newly-diagnosed AMLpatients ineligible for standard induction chemotherapy. Thecombinations of the present invention may additionally comprise low-dosecytarabine.

In certain embodiments, the combinations of the present inventioncomprise an additional anti-cancer agent. The one or more additionalcancer agents may be selected from any agents suitable for the treatmentof myeloid malignancies, preferably AML. Preferred agents may beselected from: selectin inhibitors (e.g. GMI-1271); FMS-like tyrosinekinase receptor 3 (FLT3) inhibitors (e.g. midostaurin or gilteritinib);cyclin-dependent kinase inhibitors; aminopeptidase inhibitors; JAK/STATinhibitors; cytarabine; fludarabine; anthracycline compounds (e.g.daunorubicin, idarubicin); doxorubicin; hydroxyurea; Vyxeos; IDH1 orIDH2 inhibitors such as Idhifa (or Enasidenib) or Tibsovo (orivosidenib); Smoothened inhibitors such as Glasdegib; BET bromodomaininhibitors; CD123 or CD33 targeting agents; HDAC inhibitors; LSCtargeting agents; AML bone marrow niche targeting agents;NEDD8-activating enzyme inhibitors such as Pevonedistat; G-CSF, andtopoisomerase inhibitors such as mitoxantrone, selinexor and etoposide.

Formulation of the Combination

The agents of the combinations described herein may be combined orformulated in any manner allowing the combination therapy to beadministered to a subject or patient in need thereof, preferably a humansubject or patient in need thereof. The combination may be formulatedfor single dose administration or for multiple dose administration.

In certain embodiments, the agents of the combinations may beco-formulated i.e. formulated as a single pharmaceutical composition.For embodiments wherein the agents are co-formulated, the combination orcomposition is suitable for simultaneous administration of the agents.

In preferred embodiments, the agents of the combinations describedherein are formulated as separate compositions or pharmaceuticalcompositions. For embodiments wherein the agents are formulatedseparately, the possibility exists for simultaneous or separateadministration of the different agents or compositions. If the differentcompositions are administered separately, there may be sequentialadministration of the agents in any preferred order. The intervalbetween administration of the agents may be any suitable time interval.The administration of the different compositions may be carried out once(for a single dose administration) or repeatedly (for a multiple doseadministration).

The CD70 antibodies or antigen binding fragments of the combinationsdescribed herein may be formulated using any suitable pharmaceuticalcarriers, adjuvants and/or excipients. Techniques for formulatingantibodies for human therapeutic use are well known in the art and arereviewed, for example, in Wang et al. (2007) Journal of PharmaceuticalSciences, 96:1-26, the contents of which are incorporated herein intheir entirety. Pharmaceutically acceptable excipients that may be usedto formulate the antibody compositions include, but are not limited to,ion exchangers, alumina, aluminum stearate, lecithin, serum proteins,such as human serum albumin, buffer substances such as phosphates,glycine, sorbic acid, potassium sorbate, partial glyceride mixtures ofsaturated vegetable fatty acids, water, salts or electrolytes, such asprotamine sulfate, disodium hydrogen phosphate, potassium hydrogenphosphate, sodium chloride, zinc salts, colloidal silica, magnesiumtrisilicate, polyvinyl pyrrolidone, cellulose-based substances (forexample sodium carboxymethylcellulose), polyethylene glycol,polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers,polyethylene glycol and wool fat.

The BCL-2 inhibitor (preferably venetoclax or a pharmaceuticallyacceptable salt thereof) may be formulated using any suitablepharmaceutical carriers, adjuvants and/or excipients. Suitable agentsinclude, for example, encapsulating materials or additives such asabsorption accelerators, antioxidants, binders, buffers, coating agents,coloring agents, diluents, disintegrating agents, emulsifiers,extenders, fillers, flavoring agents, humectants, lubricants, perfumes,preservatives, propellants, releasing agents, sterilizing agents,sweeteners, solubilizers, wetting agents and mixtures thereof.

In certain embodiments, the compositions are formulated foradministration to a subject via any suitable route of administrationincluding but not limited to intramuscular, intravenous, intradermal,intraperitoneal injection, subcutaneous, epidural, nasal, oral, rectal,topical, inhalational, buccal (e.g., sublingual), and transdermaladministration. In certain embodiments, the compositions are formulatedas aqueous solutions, tablets, capsules, powders or any other suitabledosage form.

Excipients for preparation of compositions comprising a BCL-2 inhibitor(preferably venetoclax) to be administered orally in solid dosage forminclude, for example, agar, alginic acid, aluminum hydroxide, benzylalcohol, benzyl benzoate, 1,3-butylene glycol, carbomers, castor oil,cellulose, cellulose acetate, cocoa butter, corn starch, corn oil,cottonseed oil, cross-povidone, diglycerides, ethanol, ethyl cellulose,ethyl laureate, ethyl oleate, fatty acid esters, gelatin, germ oil,glucose, glycerol, groundnut oil, hydroxypropylmethyl cellulose,isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesiumstearate, malt, mannitol, monoglycerides, olive oil, peanut oil,potassium phosphate salts, potato starch, povidone, propylene glycol,Ringer's solution, safflower oil, sesame oil, sodium carboxymethylcellulose, sodium phosphate salts, sodium lauryl sulfate, sodiumsorbitol, soybean oil, stearic acids, stearyl fumarate, sucrose,surfactants, talc, tragacanth, tetrahydrofurfuryl alcohol,triglycerides, water, and mixtures thereof. Excipients for preparationof compositions comprising a BCL-2 inhibitor (preferably venetoclax) tobe administered orally in liquid dosage forms include, for example,1,3-butylene glycol, castor oil, corn oil, cottonseed oil, ethanol,fatty acid esters of sorbitan, germ oil, groundnut oil, glycerol,isopropanol, olive oil, polyethylene glycols, propylene glycol, sesameoil, water and mixtures thereof. Excipients for preparation ofcompositions comprising a BCL-2 inhibitor (preferably venetoclax) to beadministered osmotically include, for example, chlorofluorohydrocarbons,ethanol, water and mixtures thereof. Excipients for preparation ofcompositions comprising a BCL-2 inhibitor (preferably venetoclax) to beadministered parenterally include, for example, 1,3-butanediol, castoroil, corn oil, cottonseed oil, dextrose, germ oil, groundnut oil,liposomes, oleic acid, olive oil, peanut oil, Ringer's solution,safflower oil, sesame oil, soybean oil, U.S. P. or isotonic sodiumchloride solution, water and mixtures thereof.

For embodiments wherein the agents of the combination are formulatedseparately i.e. as separate compositions, the separate compositions maybe formulated for the same route of administration. For embodimentswherein the agents of the combination are formulated separately i.e. asseparate compositions, the separate compositions may be formulated fordifferent routes of administration. For example, the CD70 antibody orantigen binding fragment may be formulated for intravenousadministration and the BCL-2 inhibitor (preferably venetoclax) may beformulated for oral administration.

As noted above, the combination therapies of the present invention maycomprise Venclexta®. Venclexta® is a venetoclax product marketed andsold by AbbVie Inc and Genentech. Venclexta® tablets for oraladministration are supplied as pale yellow or beige tablets that contain10, 50, or 100 mg venetoclax as the active ingredient. Each tablet alsocontains the following inactive ingredients: copovidone, colloidalsilicon dioxide, polysorbate 80, sodium stearyl fumarate, and calciumphosphate dibasic. In addition, the 10 mg and 100 mg coated tabletsinclude the following: iron oxide yellow, polyvinyl alcohol,polyethylene glycol, talc, and titanium dioxide. The 50 mg coatedtablets also include the following: iron oxide yellow, iron oxide red,iron oxide black, polyvinyl alcohol, talc, polyethylene glycol andtitanium dioxide. For embodiments wherein a CD70 antibody or antigenbinding fragment thereof is combined with Venclexta®, the CD70 antibodyor antigen binding fragment may be formulated for intravenousadministration whilst the Venclexta® is provided as one or more of thetablet forms described above.

For combinations of the invention comprising or consisting of agents inaddition to the CD70 antibodies or antigen binding fragments and a BCL-2inhibitor (preferably venetoclax), the one or more additional agents maybe formulated for administration via the same route or via a differentroute as compared with the other agents. For example, in preferredembodiments wherein the combination includes (i) an antibody or antigenbinding fragment thereof that binds to CD70; (ii) venetoclax or apharmaceutically acceptable thereof; and (iii) azacitidine, the antibodyor antigen binding fragment may be administered intravenously, thevenetoclax or pharmaceutically acceptable salt thereof may beadministered orally whilst the azacitidine may be administeredsubcutaneously via injection. In preferred embodiments wherein thecombination includes (i) an antibody or antigen binding fragment thereofthat binds to CD70; (ii) venetoclax or a pharmaceutically acceptablethereof; and (iii) decitabine, the antibody or antigen binding fragmentmay be administered intravenously, the venetoclax or pharmaceuticallyacceptable salt thereof may be administered orally whilst the decitabinemay be administered subcutaneously via injection.

C. Methods of Treatment

The combination therapies described in accordance with the first aspectof the invention can be used in methods of treating a malignancy,particularly a myeloid malignancy, in a human subject.

The present invention provides an antibody or antigen binding fragmentthereof that binds to CD70 for use in the treatment of a malignancy,particularly a myeloid malignancy, in a human subject, wherein theantibody or antigen binding fragment thereof is administered incombination with a BCL-2 inhibitor. The present invention also providesa BCL-2 inhibitor for use in the treatment of a malignancy, particularlya myeloid malignancy, in a human subject, wherein the BCL-2 inhibitor isadministered in combination with an antibody or antigen binding fragmentthat binds to CD70.

In preferred embodiments, the BCL-2 inhibitor is venetoclax or apharmaceutically acceptable salt thereof.

The present invention further provides a combination in accordance withthe first aspect of the invention for use in the treatment of amalignancy, particularly a myeloid malignancy, in a human subject.

In a yet further aspect, the present invention provides a method fortreating a malignancy, particularly a myeloid malignancy, in a humansubject, said method comprising administering to the subject acombination in accordance with the first aspect of the invention. Theinvention also provides a method for treating a malignancy, particularlya myeloid malignancy, in a human subject, said method comprising thesteps of (i) administering to the subject an antibody or antigen bindingfragment thereof that binds to CD70; and (ii) administering to thesubject a BCL-2 inhibitor, preferably venetoclax or a pharmaceuticallyacceptable salt thereof. Steps (i) and (ii) of the method may beperformed in either order.

All embodiments described above in relation to the combination of thefirst aspect of the invention are equally applicable to the methodsdescribed herein.

The term “malignancy” encompasses diseases in which abnormal cellsproliferate in an uncontrolled manner and invade the surroundingtissues. Malignant cells that have entered the body's blood and lymphsystems are capable of travelling to distal sites in the body andseeding at secondary locations. In certain embodiment, the methodsdescribed herein are for treating malignancies comprising the productionof cancer progenitor or stem cells expressing CD70, CD27, or both. Asnoted elsewhere herein, upregulated CD70 expression has been detected indifferent types of cancers including renal cell carcinomas, metastaticbreast cancers, brain tumours, leukemias, lymphomas and nasopharyngealcarcinomas. Co-expression of CD70 and CD27 has also been detected inmalignancies of the hematopoietic lineage including acute lymphoblasticlymphoma and T cell lymphoma. In certain embodiments, the methodsdescribed herein are for the treatment of any of the aforementionedmalignancies associated with CD70 expression, CD27 expression or both.

In particular embodiments, the methods described herein are for treatingmyeloid malignancies, wherein a myeloid malignancy refers to any clonaldisease of hematopoietic stem or progenitor cells. The myeloidmalignancy treated in accordance with the methods of the invention maybe a newly-diagnosed myeloid malignancy or a relapsed/refractory myeloidmalignancy.

In certain embodiments, the myeloid malignancy is selected from: acutemyeloid leukemia (AML); myelodysplastic syndromes (MDS);myeloproliferative neoplasms (MPN); chronic myeloid leukemia (CML); andchronic myelomonocytic leukemias (CMML). In preferred embodiments, themyeloid malignancy is acute myeloid leukemia (AML).

Myeloid malignancies can be categorised and diagnosed according to theWHO 2008 classification, taken in combination with the 2016 update tothis classification, see in particular Arber et al. (2016) Blood127(20):2391-2405, incorporated herein by reference.

Acute myeloid leukemia (AML) refers to haematopoietic neoplasmsinvolving myeloid cells. AML is characterised by clonal proliferation ofmyeloid precursors with reduced differentiation capacity. AML patientsexhibit an accumulation of blast cells in the bone marrow. Blast cellsalso accumulate in the peripheral blood of AML patients. Typically AMLis diagnosed if the patient exhibits 20% or more blast cells in the bonemarrow or peripheral blood.

According to the WHO classification, AML in general encompasses thefollowing subtypes: AML with recurrent genetic abnormalities; AML withmyelodysplasia-related changes; therapy-related myeloid neoplasms;myeloid sarcoma; myeloid proliferations related to Down syndrome;blastic plasmacytoid dendritic cell neoplasm; and AML not otherwisecategorized (e.g. acute megakaryoblastic leukemia, acute basophilicleukemia).

AML can also be categorised according to the French-American-British(FAB) classification, encompassing the subtypes: M0 (acute myeloblasticleukemia, minimally differentiated); M1 (acute myeloblastic leukemia,without maturation); M2 (acute myeloblastic leukemia, with granulocyticmaturation); M3 (promyelocytic, or acute promyelocytic leukemia (APL));M4 (acute myelomonocytic leukemia); M4eo (myelomonocytic together withbone marrow eosinophilia); M5 (acute monoblastic leukemia (M5a) or acutemonocytic leukemia (M5b)); M6 (acute erythroid leukemias, includingerythroleukemia (M6a) and very rare pure erythroid leukaemia (M6b)); orM7 (acute megakaryoblastic leukemia).

As used herein, “AML” refers to any of the conditions encompassed by theWHO and/or FAB classifications, unless specified otherwise. Certain AMLsubtypes are considered to be of more favourable prognosis, some ofintermediate prognosis and some of poor prognosis. The skilled person isaware of which subtypes would fall into which risk category.

Myelodysplastic syndrome (MDS) is characterised by dysplasia, cytopeniaand/or abnormal changes in bone marrow cellularity and/or myeloiddifferentiation, for example increased blast cell infiltration.According to the WHO classification, MDS in general encompasses thefollowing subtypes: MDS with single lineage dysplasia (previously called“refractory cytopenia with unilineage dysplasia”, which includesrefractory anemia, refractory neutropenia, and refractorythrombocytopenia); MDS with ring sideroblasts, which includes subgroupswith single lineage dysplasia and multilineage dysplasia (previouslycalled “refractory anemia with ring sideroblasts”); MDS withmultilineage dysplasia (previously called “refractory cytopenia withmultilineage dysplasia”); MDS with excess blasts (MDS-EB, previouslycalled “refractory anemia with excess blasts”), which can be furthersubclassified into MDS-EB-1 and MDS-EB-2 based on blast percentages; MDSwith isolated del(5q); and MDS, unclassified.

MDS can also be categorised according to the French-American-British(FAB) classification, encompassing the subtypes: M9980/3 (refractoryanaemia (RA)); M9982/3 (refractory anaemia with ring sideroblasts(RARS)); M9983/3 (refractory anaemia with excess blasts (RAEB)); M9984/3(refractory anaemia with excess blasts in transformation (RAEB-T)); andM9945/3 (chronic myelomonocytic leukemia (CMML)).

As used herein, “MDS” refers to any of the conditions encompassed by theWHO and/or FAB classifications, unless specified otherwise. For both AMLand MDS, the WHO categorisation is preferred herein.

Myeloproliferative neoplasms (MPN) are similar to MDS but according tothe WHO classification, MPN in general encompasses the followingsubtypes: chronic myeloid leukemia (CML); chronic neutrophilic leukemia(CNL); polycythemia vera (PV); primary myelofibrosis (PMF); Essentialthrombocythemia (ET); chronic eosinophilic leukemia, not otherwisespecified; and MPN unclassifiable.

Chronic myelomonocytic leukemia (CMML) and atypical chronic myeloidleukemia (aCML) fall within the category of MDS/MPN disorders accordingto the WHO classification, for the reason that they represent myeloidneoplasms with clinical, laboratory and morphologic features thatoverlap between MDS and MPN.

Patient Characteristics

The patients or subjects treated in accordance with the methodsdescribed herein, particularly those having AML, may havenewly-diagnosed disease, relapsed disease or primary refractory disease.

A standard approach to treatment for newly-diagnosed AML patients is the“standard 7+3 intensive chemotherapy” approach characterised by 7 daysof high dose cytarabine followed by 3 days of anthracyclineadministration (e.g. daunorubicin or idarubicin). Intensive chemotherapyis given with the aim of inducing complete remission of AML, typicallywith the intention of the patient undergoing a stem cell transplantfollowing successful chemotherapy.

Standard intensive chemotherapy is associated with significant toxicityand side-effects, meaning it is not suitable for patients unable totolerate these effects. These patients are termed “ineligible forstandard intensive chemotherapy”. A patient may be ineligible forstandard intensive chemotherapy because, for example, they exhibit oneor more comorbidities indicating they would not tolerate the toxicity,or the prognostic factors characterising their disease indicate anunfavourable outcome of standard intensive chemotherapy. Determinationof an individual patient's eligibility for standard intensivechemotherapy would be performed by a clinician taking into account theindividual patient's medical history and clinical guidelines (e.g. theNational Comprehensive Cancer Network (NCCN) guidelines, incorporatedherein by reference). AML patients over the age of 60 are often assessedas ineligible for standard intensive chemotherapy, with other factors tobe considered including the cytogenetics and/or molecular abnormalitiesof the AML being treated.

A patient ineligible for standard intensive chemotherapy may insteadreceive chemotherapy of reduced intensity, such as low dose cytarabine(LDAC). Patients ineligible for standard intensive chemotherapy and forwhom LDAC is not appropriate can receive best supportive care (BSC),including hydroxyurea (HU) and transfusion support.

Patients or subjects treated in accordance with the methods describedherein may be those classified as “ineligible for standard intensivechemotherapy”. The combinations of the invention comprise targetedtherapies that may be predicted to have fewer side-effects. As such,patients deemed ineligible for standard intensive chemotherapy, for anyof the reasons identified above, may be treated with the combinationsaccording to the present invention.

As discussed above, venetoclax is authorised in the US for use incombination with azacitidine, decitabine or low-dose cytarabine for thetreatment of newly-diagnosed AML in adults who are aged 75 years orolder or who have comorbidities that preclude use of intensive inductionchemotherapy. Thus, in certain embodiments, particularly embodimentswherein the BCL-inhibitor is venetoclax or a pharmaceutically acceptablesalt thereof, patients or subjects treated in accordance with themethods described herein are newly-diagnosed AML patients aged 75 yearsor older. In further embodiments, patients or subjects treated inaccordance with the methods described herein are newly-diagnosed AMLpatients having comorbidities that preclude use of intensive inductiontherapy. Patients having a comorbidity precluding use of intensiveinduction chemotherapy may be classified as such based on at least oneof the following criteria: baseline Eastern Cooperative Oncology Group(ECOG) performance status of 2-3, severe cardiac or pulmonarycomorbidity, moderate hepatic impairment, or CLcr<45 ml/min. Suchembodiments are particularly preferred when the BCL-2 inhibitor in thecombination according to the invention is venetoclax or apharmaceutically acceptable salt thereof.

Patients or subjects treated in accordance with the methods describedherein may be eligible for other treatments, for example standardintensive chemotherapy, but may receive the combination therapiesdescribed herein as an alternative treatment option. For example,patients or subjects treated in accordance with the methods describedherein may be newly-diagnosed AML patients otherwise eligible forstandard intensive chemotherapy.

Additional Agents for Treatment

The methods described herein may include administration of one or moreadditional therapeutic agents, for example, additional anti-canceragents. In certain embodiments, the methods comprise the administrationof one or more agents for use in treating myeloid malignancies, forexample agents suitable for use in treating AML. Such agents include butare not limited to: selectin inhibitors (e.g. GMI-1271); FMS-liketyrosine kinase receptor 3 (FLT3) inhibitors (e.g. midostaurin orgilteritinib); cyclin-dependent kinase inhibitors; aminopeptidaseinhibitors; JAK/STAT inhibitors; cytarabine; fludarabine; anthracyclinecompounds (e.g. daunorubicin, idarubicin); doxorubicin; hydroxyurea;Vyxeos; IDH1 or IDH2 inhibitors such as Idhifa (or Enasidenib) orTibsovo (or ivosidenib); Smoothened inhibitors such as Glasdegib; BETbromodomain inhibitors; CD123 or CD33 targeting agents; HDAC inhibitors;LSC targeting agents; AML bone marrow niche targeting agents;NEDD8-activating enzyme inhibitors such as Pevonedistat; G-CSF, andtopoisomerase inhibitors such as mitoxantrone, selinexor and etoposide.

In preferred embodiments, the methods described herein compriseadministration of a further agent that is a nucleoside metabolicinhibitor, preferably a hypomethylating agent. Particularly preferredhypomethylating agents are azacitidine and decitabine. As describedherein above, in certain embodiments the combinations of the inventioncomprising (i) a CD70 antibody or antigen binding fragment thereof; and(ii) a BCL-2 inhibitor, preferably venetoclax or a pharmaceuticallyacceptable salt, may be formulated so as to include additional agents,for example azacitidine or decitabine.

Alternatively, for embodiments wherein the combination consists of (i)an antibody or antigen binding fragment that binds to CD70; and (ii) aBCL-2 inhibitor, preferably venetoclax or a pharmaceutically acceptablesalt thereof, the methods wherein the combination is administered to asubject, may comprise a further step of administering the additionalagent, for example azacitidine or decitabine. Thus, in a preferredembodiment, the present invention provides a method for treating amyeloid malignancy, preferably AML, in a human subject, said methodcomprising administering to the subject: (i) an antibody or antigenbinding fragment thereof that binds to CD70; (ii) a BCL-2 inhibitor,preferably venetoclax or a pharmaceutically acceptable salt thereof; and(iii) azacitidine or decitabine. Also provided herein is a combinationfor use in treating a myeloid malignancy, preferably AML, in a humansubject, said combination comprising: (i) an antibody or antigen bindingfragment thereof that binds to CD70; (ii) a BCL-2 inhibitor, preferablyvenetoclax or a pharmaceutically acceptable salt thereof; and (iii)azacitidine or decitabine.

Dosing

As demonstrated in the Examples, combinations of the invention exhibitsynergistic treatment efficacy against AML cells—that is, the level ofinhibition induced by the combination is greater than the additiveeffect of the monotherapies alone.

Methods for determining synergistic interaction are familiar to theskilled person and are described in the Examples. A preferred method fordetermining whether synergistic effects arise from a combination is theChou-Talalay method (Chou, TC. Cancer Res. 2010 Jan. 15; 70(2):440-6,incorporated herein by reference).

According to the Chou-Talalay method, a CI of <1 shows synergy, CI=1shows an additive effect, and a CI>1 shows antagonism. As presented inFIG. 1 , the presence and extent of the synergy arising fromcombinations of the invention varies according to the strength of theinhibitory effect of the combination. The strength of the combination'sinhibitory effect itself is dependent on the total concentration of thecombination.

Preferably, therefore, in embodiments of all aspects of the invention,the dose at which the CD70 antibody or antigen binding fragment thereofis administered and/or provided in the combination, and the dose atwhich the BCL-2 inhibitor is administered and/or provided in thecombination, are each selected such that the combination providessynergistic treatment—that is, where the combination exhibits a CI ofless than 1 as determined by the Chou-Talalay method. Preferably thedoses are such that the combination exhibits a CI of less than 0.5.

Preferably, in certain embodiments, the dose at which the CD70 antibodyor antigen binding fragment thereof is administered and/or provided inthe combination, and the dose at which the BCL-2 inhibitor isadministered and/or provided in the combination, are each selected suchthat the combination exhibits a CI of less than 1 and Fa of >0.5, asdetermined by the Chou-Talalay method.

As shown in the Examples, synergy was also observed for a combination ofan anti-CD70 antibody (ARGX-110), a BCL-2 inhibitor (venetoclax) and anHMA (decitabine). Therefore, in certain preferred embodiments of aspectsof the invention where the combination includes an HMA, the dose atwhich the CD70 antibody or antigen binding fragment thereof isadministered and/or provided in the combination, the dose at which theBCL-2 inhibitor is administered and/or provided in the combination, andthe dose at which the HMA is administered and/or provided in thecombination are each selected such that the combination providessynergistic efficacy in treatment.

It has been found that CD70 antibodies, particularly ARGX-110, areeffective for the treatment of myeloid malignancy, particularly AML, atrelatively low dose. Therefore, in certain embodiments of all methods ofthe invention the CD70 antibody or antigen binding fragment thereof isadministered at a dose in the range from 0.1 mg/kg to 25 mg/kg per dose,for example in the range of from 0.1 mg/kg to 20 mg/kg. In certainembodiments, the CD70 antibody or antigen binding fragment thereof isadministered at a dose in the range from 1 mg/kg to 20 mg/kg per dose.Ranges described herein include the end points of the range unlessindicated otherwise—for example, administration at a dose in the rangeof 0.1-25 mg/kg includes administration at a dose of 0.1 mg/kg andadministration at a dose of 25 mg/kg, as well as all doses between thetwo end points.

In certain embodiments of methods of the invention, the CD70 antibody orantigen binding fragment thereof is administered at a dose in the rangefrom 0.1 mg/kg to 15 mg/kg. In certain embodiments the CD70 antibody orantigen binding fragment thereof is administered at a dose in the rangefrom 0.5 mg/kg to 2 mg/kg. In certain embodiments the CD70 antibody orantigen binding fragment thereof is administered at a dose of 1 mg/kg, 3mg/kg, 10 mg/kg, or 20 mg/kg. In certain preferred embodiments the CD70antibody or antigen binding fragment thereof is administered at a doseof 1 mg/kg. In certain preferred embodiments the CD70 antibody orantigen binding fragment thereof is administered at a dose of 10 mg/kg.

In certain embodiments, multiple doses of the CD70 antibody or antigenbinding fragment are administered. In certain such embodiments, eachdose of the CD70 antibody or antigen-binding fragment thereof isseparated by 10-20 days, optionally 12-18 days. In certain embodimentseach dose of anti-CD70 antibody is separated by 14-17 days.

The BCL-2 inhibitor, preferably venetoclax or pharmaceuticallyacceptable salt thereof, of the combination may be dosed according toany regimen determined to be effective for the compound. The FDAprescribing information for use of Venclexta® in treating AML proposes adosing schedule having a ramp-up phase followed by a maintenance phase.In situations where Venclexta® is prescribed in combination withazacitidine or decitabine, a dosing schedule is recommended consistingof: 100 mg Venclexta® on day 1; 200 mg Venclexta® on day 2; 400 mgVenclexta® on day 3; and 400 mg Venclexta® in combination with 75 mg/m²azacitidine or 20 mg/m² decitabine daily thereafter until diseaseprogression or unacceptable toxicity is observed. In situations whereVenclexta® is prescribed in combination with low-dose cytarabine, adosing schedule is recommended consisting of: 100 mg Venclexta® on day1; 200 mg Venclexta® on day 2; 400 mg Venclexta® on day 3; and 600 mgVenclexta® in combination with 20 mg/m² daily thereafter until diseaseprogression or unacceptable toxicity is observed.

In certain embodiments, each dose, for example oral dose, of thevenetoclax or pharmaceutically acceptable salt thereof is in the rangefrom 100 mg-600 mg. In certain embodiments, the venetoclax orpharmaceutically acceptable salt thereof is dosed daily at 400 mg. Incertain embodiments, the venetoclax or pharmaceutically acceptable saltthereof is dosed daily at 600 mg. As described above, the dailyfixed-dosing of venetoclax may be preceded by a ramp-up period, forexample 3 days, wherein increasing doses of venetoclax are administeredto the patient until the maintenance daily dose is reached.

For embodiments of the invention wherein the combination comprises anucleoside metabolic inhibitor or the method comprises administering anucleoside metabolic inhibitor, the nucleoside metabolic inhibitor maybe administered at a dose in the range of 20-100 mg/m² per day. Asalready noted, ranges described herein include the end points of therange unless indicated otherwise—for example, administration at a dosein the range of 20-100 mg/m² per day includes administration at a doseof 20 mg/m² per day and administration at a dose of 100 mg/m² per day,as well as all doses between the two end points.

In certain embodiments, the nucleoside metabolic inhibitor isazacitidine and is administered at a dose in the range of 70-80 mg/m²per day. In certain preferred embodiments the nucleoside metabolicinhibitor is azacitidine and is administered at a dose of 75 mg/m² perday.

In certain embodiments, the nucleoside metabolic inhibitor is decitabineand is administered at a dose in the range of 15-25 mg/m² per day. Incertain preferred embodiments the nucleoside metabolic inhibitor isdecitabine and is administered at a dose of 20 mg/m² per day.

For embodiments wherein the combination of the invention includes anucleoside metabolic inhibitor or the method involves administration ofa nucleoside metabolic inhibitor, the nucleoside metabolic inhibitor maybe administered over a dosing period of a daily dose for 5-10 days. Thatis, a dose of the nucleoside inhibitor is administered every day for aperiod or 5, 6, 7, 8, 9, or 10 days in length. In certain preferredembodiments the nucleoside metabolic inhibitor is administered over adosing period of a daily dose for 7 days. The preferred nucleosidemetabolic inhibitor is azacitidine.

In certain embodiments, the nucleoside metabolic inhibitor isadministered according to a dosage regimen of repeated dosing periods,wherein the end of one dosing period and the start of the next dosingperiod are separated by 18-25 days. That is, the dosage regimen includesat least 2 dosing periods in which a dose of the nucleoside inhibitor isadministered every day (for example for a period 5, 6, 7, 8, 9 or 10days in length), wherein the end of the one dosing period and the startof the next dosing period are separated by 18, 19, 20, 21, 22, 23, 24,or 25 days. In certain embodiments the end of one dosing period and thestart of the next dosing period are separated by 21 days.

In certain embodiments, each dosing period is of the same length (e.g. 7days). In certain embodiments, the end of each dosing period and thestart of the next dosing period are separated by the same number of days(e.g. 21 days).

In certain embodiments, the first dose of nucleoside metabolic inhibitoris administered 7-21 days after the first dose of CD70 antibody orantigen binding fragment thereof. In certain embodiments the first doseof nucleoside metabolic inhibitor is administered 10-17 days after thefirst dose of CD70 antibody or antigen binding fragment thereof. Incertain embodiments the first dose of nucleoside metabolic inhibitor isadministered 14 days after the first dose of CD70 antibody or antigenbinding fragment thereof.

In certain embodiments, one of the daily doses of the nucleosidemetabolic inhibitor is administered on the same day as a dose of theCD70 antibody or antigen binding fragment thereof. That is, inembodiments of the methods of the invention in which the subject isadministered both a CD70 antibody (or antigen binding fragment thereof)and a nucleoside metabolic inhibitor, the dosage regimes of both theCD70 antibody and the nucleoside metabolic inhibitor are such that atleast one of the scheduled doses of the CD70 antibody is on the same dayas one of the scheduled daily doses of the nucleoside metabolicinhibitor. That day could be the first, second, third, fourth, fifth,sixth or seventh day of the dosing period of the nucleoside metabolicinhibitor.

In certain embodiments, a dose of the CD70 antibody or antigen bindingfragment thereof is administered every 14-17 days and the nucleosidemetabolic inhibitor is administered according to a dosage regimen ofrepeated dosing periods of a daily dose for 7 days, wherein the end ofone dosing period and the start of the next dosing period are separatedby 21 days, and wherein the first daily dose of the first dosing periodis administered 14 days after the first dose of the anti-CD70 antibodyor antigen-binding fragment thereof.

In certain embodiments, one patient treatment cycle consists of 28 daysand the nucleoside metabolic inhibitor, preferably azacitidine ordecitabine, is administered every day for a period of 5, 6, 7, 8, 9 or10 days beginning on day 1 of the cycle. The methods of treatmentdescribed herein may comprise multiple treatment cycles. Each treatmentcycle may replicate the preceding treatment cycle. In certainembodiments, a patient treated with a CD70 antibody, a BCL-inhibitor(preferably venetoclax or a pharmaceutically acceptable salt thereof)and azacitidine is treated according to a cycle consisting of 28 dayswherein azacitidine is administered daily on the first 7 days of the28-day cycle. In certain embodiments, a patient treated with a CD70antibody, a BCL-inhibitor (preferably venetoclax or a pharmaceuticallyacceptable salt thereof) and decitabine is treated according to a cycleconsisting of 28 days wherein decitabine is administered daily on thefirst 5 days of the 28-day cycle. For embodiments wherein the patient istreated according to a 28-day cycle with a CD70 antibody, aBCL-inhibitor ((preferably venetoclax or a pharmaceutically acceptablesalt thereof) and a nucleoside metabolic inhibitor (preferablyazacitidine or decitabine), the CD70 antibody may be administered on day3 and/or day 17 of the 28-day cycle. In preferred embodiments, the CD70antibody is ARGX-110. In further preferred embodiments, the CD70antibody (for example ARGX-110) is administered at a dose of 10 mg/kg.

It is a further advantage of the invention that following an initialperiod of combination therapy, the administration of an NMI (e.g.azacitidine) can be tapered or stopped. There is the potential foraccumulated toxicity arising from prolonged periods of NMI treatment,for example cytopenias arising from the effect of NMIs on non-blast celltypes. Therefore, by tapering or stopping the dose of NMI after aninitial period, the risk of such toxicity will be reduced and non-blastcell types can recover. In certain embodiments, treatment according tothe invention comprises administering to the patient a CD70 antibody, aBCL-2 inhibitor (for example venetoclax) and a NMI as a combinationtherapy according to any of the embodiments described above in a firststage (induction therapy), and in a subsequent second stageadministering to the patient a CD70 antibody, a BCL-2 inhibitor (forexample venetoclax) and a NMI as a combination therapy but wherein thedose of the NMI in the second stage (maintenance therapy) is lower thanthe dose of NMI administered in the first stage. The dose of the NMI inthe second stage may be zero.

In such embodiments, the dose of CD70 antibody administered in thesecond stage (i.e. maintenance therapy) is any dose according to theembodiments already described. That is, in certain embodiments the doseis in the range from 0.1 mg/kg to 25 mg/kg, for example 0.1 mg/kg to 20mg/kg, for example from 1 mg/kg to 20 mg/kg. In certain embodiments thedose is in the range of from 0.1 mg/kg to 15 mg/kg per dose. In certainembodiments the dose is in the range from 0.5 mg/kg to 2 mg/kg. Incertain embodiments the dose is 1 mg/kg, 3 mg/kg, 10 mg/kg, or 20 mg/kg.In certain embodiments the dose is 1 mg/kg. In certain embodiments thedose is 10 mg/kg.

The duration of the first stage (i.e. induction therapy), the timing ofthe transition to the second stage (i.e. maintenance therapy) and theextent to which the dose of NMI is tapered or stopped entirely arefactors that will be tailored to the individual patient and determinedby their clinician according to the individual patient's response totherapy and their medical history. Therefore the following embodimentsare provided by way of non-limiting example. In certain embodiments theinduction therapy is administered to the patient until their bone marrowand/or peripheral blood blast percentage is less than 10%, optionallyless than 5%. In certain embodiments, the induction therapy isadministered for at least 5 NMI dosing periods, optionally at least 6,7, 8, 9, or at least 10 NMI dosing periods.

In certain embodiments, the dose of the NMI in the maintenance period isno more than 50 mg/m² per day, optionally no more than 40 mg/m² per day,optionally no more than 30 mg/m2 per day, optionally no more than 20mg/m² per day. In certain embodiments, the dose of the NMI in themaintenance period is zero.

As explained elsewhere herein, the agents of the combinations may beformulated for administration by any suitable routes of administration.Thus, the administration of the agents in accordance with the methods ofthe invention can be via any suitable routes and need not be via thesame route for individual agents. For example, the CD70 antibody orantigen binding fragment thereof may be administered intravenouslywhilst the BCL-2 inhibitor (e.g. venetoclax) is administered orally. Forembodiments wherein the patient or subject receives a hypomethylatingagent such as azacitidine or decitabine, such agent may be administeredintravenously or subcutaneously via injection.

Treatment Outcomes

In certain embodiments, the methods described herein involve monitoringthe patient's blast count i.e. the number of blast cells. As usedherein, “blast cells” or “blasts” refer to myeloblasts or myeloid blastswhich are the myeloid progenitor cells within the bone marrow. Inhealthy individuals, blasts are not found in the peripheral bloodcirculation and there should be less than 5% blast cells in the bonemarrow. In subjects with myeloid malignancies, particularly AML and MDS,there is increased production of abnormal blasts with disrupteddifferentiation potential, and the overproduction of these abnormalblasts can be detected by monitoring the patient's blast count in theperipheral blood circulation or the bone marrow or both.

The proportion of blast cells in the bone marrow or peripheral blood canbe assessed by methods known in the art, for example flow cytometric orcell morphologic assessment of cells obtained from a bone marrow biopsyof the subject, or a peripheral blood smear. The proportion of blasts isdetermined versus total cells in the sample. For example, flow cytometrycan be used to determine the proportion of blast cells using the numberof CD45^(dim), SSC^(low) cells relative to total cell number. By way offurther example, cell morphological assessment can be used to determinethe number of morphologically identified blasts relative to the totalnumber of cells in the field of view being examined.

In certain embodiments are provided methods for reducing the proportionof blasts cells in the bone marrow to less than 25%, less than 20%, forexample less than 10%. In certain embodiments are provided methods forreducing the proportion of blasts cells in the bone marrow to less than5%. In certain embodiments are provided methods for reducing theproportion of blast cells in the bone marrow to between about 5% andabout 25%, wherein the bone marrow blast cell percentage is also reducedby more than 50% as compared with the bone marrow blast cell percentageprior to performing the method (or pretreatment).

In certain embodiments are provided methods for reducing the proportionof blasts cells in the peripheral blood to less than 25%, less than 20%,for example less than 10%. In certain embodiments are provided methodsfor reducing the proportion of blasts cells in the peripheral blood toless than 5%. In certain embodiments are provided methods for reducingthe proportion of blast cells in the peripheral blood to between about5% and about 25%, wherein the peripheral blood blast cell percentage isalso reduced by more than 50% as compared with the peripheral blast cellpercentage prior to performing the method (or pretreatment).

For clinical determination of blast cell percentage, typically cellmorphological (also known as cytomorphology) assessment is preferred.

In particular embodiments, the methods described herein induce acomplete response. In the context of AML treatment, a complete responseor “complete remission” is defined as: bone marrow blasts <5%; absenceof circulating blasts and blasts with Auer rods; absence ofextramedullary disease; ANC≥1.0×10⁹/L (1000 μL); platelet count≥100×10⁹/L (100,000 μL), see Döhner et al. (2017) Blood 129(4): 424-447.

The methods may achieve a complete response with platelet recovery i.e.a response wherein the platelet count is >100×10⁹/L (100,000/μL). Themethods may achieve a complete response with neutrophil recovery i.e. aresponse wherein the neutrophil count is >1.0×10⁹/L (1000/μL).Alternatively or in addition, the methods may induce a transfusionindependence of red blood cells or platelets, or both, for 8 weeks orlonger, 10 weeks or longer, 12 weeks or longer.

In particular embodiments, the methods described herein induce a minimalor measurable residual disease (or MRD) status that is negative, seeSchuurhuis et al. (2018) Blood. 131(12): 1275-1291.

In certain embodiments, the methods described herein induce a completeresponse without minimal residual disease (CR_(MRD−)), see Döhner et al.ibid.

The method may achieve a partial response or induce partial remission.In the context of AML treatment, a partial response or partial remissionincludes a decrease of the bone marrow blast percentage of 5% to 25% anda decrease of pretreatment bone marrow blast percentage by at least 50%,see Döhner et al. ibid.

The methods described herein may increase survival. The term “survival”as used herein may refer to overall survival, 1-year survival, 2-yearsurvival, 5-year survival, event-free survival, progression-freesurvival. The methods described herein may increase survival as comparedwith the gold-standard treatment for the particular disease or conditionto be treated. The gold-standard treatment may also be identified as thebest practice, the standard of care, the standard medical care orstandard therapy. For any given disease, there may be one or moregold-standard treatments depending on differing clinical practice, forexample in different countries. The treatments already available formyeloid malignancies are varied and include chemotherapy, radiationtherapy, stem cell transplant and certain targeted therapies.Furthermore, clinical guidelines in both the US and Europe govern thestandard treatment of myeloid malignancies, for example AML, seeO'Donnell et al. (2017) Journal of the National Comprehensive CancerNetwork 15(7):926-957 and Döhner et al. (2017) Blood 129(4):424-447,both incorporated by reference.

The methods of the present invention may increase or improve survivalrelative to patients undergoing any of the standard treatments formyeloid malignancy.

The methods described herein may include a further step of subjectingthe patient or subject to a bone marrow transplant. The methodsdescribed herein may also be used to prepare a patient or subject havinga myeloid malignancy for a bone marrow transplantation. As describedabove, the methods of the present invention may be carried out so as toreduce the absolute or relative numbers of blast cells in the bonemarrow or peripheral blood. In certain embodiments, the methods arecarried out so as to reduce the blast cell count in the bone marrowand/or peripheral blood prior to transplant. The methods may be used toreduce the blast cell count to less than 5% to prepare the patient orsubject for a bone marrow transplant.

D. Kits

The combinations of the invention described herein may be provided inthe form of a kit packaged so as to include instructions for use.

INCORPORATION BY REFERENCE

Various publications are cited in the foregoing description andthroughout the following examples, each of which is incorporated byreference herein in its entirety.

Examples

In a recent Phase 1 clinical trial, treatment of older and unfit AMLpatients with the ADCC-enhanced humanized monoclonal anti-CD70 antibody(mAb) cusatuzumab (also referred to herein as ARGX-110) in combinationwith HMA demonstrated promising clinical activity and a favorabletolerability profile.

The BCL-2 antagonist, venetoclax, targets and eliminates leukemic stemcells (LSCs) by suppression of oxidative phosphorylation anddemonstrated very promising activity in older AML patients in clinicalphase I and II studies in combination with standard of care (Pollyea etal., Nature Medicine (2018) 24; 1859-1866). However, even with novelagents such as venetoclax, there are still patients that becomerefractory or relapse. It was hypothesized that combining venetoclax andcusatuzumab with distinct but complementary mechanisms of action couldsuccessfully eliminate LSCs.

Methods

To test this hypothesis, a drug-combination study was carried outaccording to the Chou-Talalay method (Chou T C, Cancer Research (2010)70(2); 440-6) in CD70-expressing AML cell lines such as MOLM-13, NB-4,and NOMO-1 cells in vitro. MOLM-13 AML cells express FLT3-ITD and NOMO-1cells express t(9;11)(p22;q23). Each of these genetic aberrationsconveys a poor prognosis to patient outcome. NB-4 is an acutepromyelocytic leukemia (APL) cell line, where APL is a subset of AMLpatients. Of note, NOMO-1 and MOLM-13 cells express high levels of CD70as measured at the mRNA and protein levels. The MOLM-13 AML cells alsoexpress BCL-2 and are sensitive to BCL-2 inhibition (Lin et al.Scientific Reports (2016) 6; 27696).

MOLM-13 (Matsuo et al., Leukemia (1997) 11(9): 1469-77), NOMO-1 (Kato etal., Acta Haematol Jpn, 1986), MV4-11 and NB4 (Lanotte et al., Blood(1991) 77(5); 1080-86) cells were purchased from ATCC. The cell lineswere tested mycoplasma-free and were grown in FCS-containing mediumrecommended by ATCC with GlutaMAX supplement, 100 U/mL penicillin, and100 μg/mL of streptomycin in a humidified atmosphere of 95% air and 5%CO₂ at 37° C.

Initially, cells from each AML cell line were treated with decitabine,cusatuzumab or venetoclax alone to determine the IC₅₀ for eachtreatment. 10⁵ AML cells were treated with a concentration range ofcusatuzumab (0.1, 1.0 and 10 μg/ml), venetoclax (0.5 and 200 nM),decitabine (0.01-1 μM) or vehicle in the presence of CFSE-labelled NKcells derived from healthy individuals (ratio 1:1). The assay wasperformed in triplicate.

The IC₅₀ determination identified the following working concentrationsfor the subsequent synergy experiments:

-   -   1) IC₅₀s, MOLM-13: (decitabine: 0.01 nM, venetoclax: 0.42 nM,        cusatuzumab: 0.68 μg/ml)    -   2) IC₅₀s, NOMO-1: (decitabine: 0.001 nM, venetoclax: 3.4 nM,        cusatuzumab: 0.14 μg/ml)    -   3) IC₅₀s, NB4: (decitabine: 4.8 nM, venetoclax: 17.3 nM,        cusatuzumab: 0.3 μg/ml)    -   4) IC₅₀s, MV4-11: (decitabine: 2.36 nM, venetoclax: 5 nM,        cusatuzumab: 1.2 μg/ml)

To determine synergy, a constant combination ratio experiment wascarried out at equipotency ratio (IC50₁/IC50₂, or IC50₁/IC50₂/IC50₃) sothat each drug contributed equally to cell killing. Combination drugdose responses were assessed in two technical replicates for everydose/dose combination as previously described (Riether et al., SciTransl Med (2015) 7(298); 298ra119.

NOMO-1, MOLM-13, NB-4 or MV4-11 AML cell lines were treated withvehicle, decitabine, cusatuzumab or venetoclax alone, a doublecombination of venetoclax and decitabine, decitabine and cusatuzumab, orvenetoclax and cusatuzumab, or a triple combination of decitabine,cusatuzumab and venetoclax. All combinations were tested at three highand three low concentrations (above and below the identified IC₅₀s) andin a constant ratio. Cells were cultured in the presence of CFSE-labeledNK cells (ratio 1:1). Viable AML cell numbers were assessed 72 hourslater by Annexin V staining, and the effect of drug treatment wascalculated as the ratio of surviving cells to vehicle-treated cells.

The Combination Index (CI) was calculated and plotted against Fractionaffected (Fa) using CompuSyn software. The resultant plot of thecombination index (CI) against fraction affected (Fa) for allcombinations is shown in FIG. 1 , with the individual combinations shownin FIGS. 2A-2D.

Fa values of 0, 0.5, and 1 correspond to 0, 50, and 100% killed cells. ACI of <1, 1, >1 represents synergism, additivity, and antagonism,respectively. IC₅₀s indicates Fa values reached for the combination ofrespective IC₅₀ concentrations. The principles and advantages of theFa-CI plot method of assessing synergism are provided in, for example,Chou T C, Cancer Research (2010) 70(2); 440-6 and Zhao et al. FrontBiosci (Elite Ed). (2010) 2; 241-249 (each of which is incorporatedherein by reference in its entirety).

In addition, the effect of the cusatuzumab/venetoclax and thecusatuzumab/venetoclax/HMA combination was tested on primary LSCs fromAML patients. Primary CD34⁺CD38⁻ leukemic stem cells (LSCs) wereisolated from newly-diagnosed AML patients and treated with cusatuzumab,decitabine, or venetoclax monotherapy or in combination. The effect oncolony formation and re-plating capacity of the LSCs was then assessed.

Specifically, CD34⁺CD38⁻ AML LSCs from three AML patients (P1, P2 andP3) were cultured overnight in the presence of NK cells (ratio 1:1) withcusatuzumab (Cusa: 0.3 μg/ml) or venetoclax (Ve: 6 nM) as monotherapy orin combination overnight in duplicates followed by plating inmethylcellulose. CD34⁺CD38⁻ AML LSCs from two further AML patients (P4and P5) were cultured overnight in the presence of NK cells (ratio 1:1)with cusatuzumab (Cusa: 0.3 μg/ml), decitabine (0.01 μM), or venetoclax(Ve: 6 nM) as monotherapy or in combination. Colony formation wasassessed 14 days later.

Results

1. Cusatuzumab Used in Combination with Venetoclax and/or DecitabineDemonstrated Synergy in the Elimination of AML Cell Lines In Vitro

Venetoclax and/or decitabine in combination with cusatuzumabsynergistically eliminated CD70-expressing NOMO-1 AML cells in a broaddose range (see FIG. 1 and FIG. 2B-2D).

At the higher effect levels (Fa>0.7), which are more relevant in tumorkilling (Chou, 2010), the combinations demonstrated strong synergy.Importantly, the CI of the venetoclax and cusatuzumab (Ven/Cusa) andvenetoclax, cusatuzumab and decitabine (Ven/Cusa/Dec) were approaching0.1, indicating very strong synergy. Venetoclax and decitabine (Ven/Dec)and cusatuzumab and decitabine (Cusa/Dec) also achieved synergy athigher effect levels, with a maximal CI ˜0.5. The synergistic effect ofthe Ven/Cusa combination was similar to the synergistic effect observedfor Ven/Cusa/Dec combination.

Similar results were observed in the NB4 and MV4-11 AML cell lines, withall cusatuzumab combinations exhibiting potent synergy at high effectlevels (Fa>0.5) (see FIGS. 3A-3D and FIG. 5 ).

In the MOLM-13 cell line, all double combinations showed a synergisticeffect at lower effect levels. Venetoclax/decitabine andcusatutzumab/decitabine showed a synergy only at drug concentrationsbelow a Fa of 0.4 and 0.6, respectively. At higher effect levels (Fa˜0.7 to 0.8), which are more relevant in tumor killing, the combinationof cusatutzumab/venetoclax demonstrated strong synergy (see FIGS.4A-4D), though some antagonism was observed at the highest effectlevels. The triple combination of venetoclax, decitabine and cusatuzumabshowed low levels of antagonism at all effect levels.

2. Cusatuzumab Used in Combination with Venetoclax and/or DecitabineDemonstrated Synergy in the Elimination of Primary Human AML LeukemicStem Cells (LSCs) In Vitro

To assess the effect of the cusatuzumab/venetoclax combination onprimary human AML LSCs, CD34⁺CD38⁻ LSCs from five AML patients weretreated (P1-P5). The patient characteristics are shown below.

TABLE 2 Patient characteristics P1-P5 ID Age (y) Sex FAB RiskCytogenetics Mutations 1 72 M M4 Int. NK ASXL1, DNMT3A, IDH2, SRSF2 2 62M M4 Adv. Monosomy 7 — 3 50 M M2 Adv. del(16), IDH2, t(11; 16), DNMT3Atrisomy 14 4 75 M Sec. AML. Int NK DNMT3a, U2AF1 5 80 F M2 Adv. NKFLT3-ITD

The results for patients P1, P2 and P3 are shown in FIGS. 6A-6B andFIGS. 7A-7B. FIG. 6 shows the absolute numbers of colonies formed perwell following treatment, indicative of the number of LSCs. FIG. 7 showsthe same data expressed as a ratio of the mean colonies per well for thevehicle treated group for each patient.

FIGS. 6 and 7 show that the synergistic effect between cusatuzumab andvenetoclax observed in the AML cell lines translated into a potent andsignificant reduction in the number of LSCs compared to either treatmentalone (FIG. 6A and FIG. 7A).

FIGS. 6B and 7B show that the effect of reducing LSC numbers wasmaintained when the first colonies were re-plated in the absence of thetreatment molecules.

The results for patients P4 and P5 are shown in FIGS. 8A-8B. In thesepatients, the triple combination of cusatuzumab, decitabine andvenetoclax showed equivalent efficacy to the dual combination ofcusatuzumab and venetoclax. This is in line with the fact that noincrease in synergy was observed for the triple combination compared tothe Ven/Cusa combination (FIG. 1 ).

3. Venetoclax Increased CD70 Expression

The effect of venetoclax on expression of CD70 at both the mRNA andprotein level was assessed. The results are shown in FIG. 9 and FIG. 10, and clearly demonstrate that CD70 expression was up-regulated in AMLcells in the presence of venetoclax.

CONCLUSIONS

The present experiments were performed to determine whether combinationtherapy with cusatuzumab and venetoclax and/or a hypomethylating agent(e.g. azacitidine or decitabine) could provide effective treatment forAML greater than each monotherapy alone. It was further explored whetherthe combination treatments could exhibit synergistic therapeuticeffects.

The Combination Index (CI) provided by the Chou-Talalay method is anestablished means for determining whether drug combinations interact ina synergistic, additive or antagonistic manner. It was hypothesised thatvenetoclax and cusatuzumab may act in a synergistic manner sincemechanistically it could be shown that treatment with venetoclax resultsin up-regulation of CD70 on AML cells (FIGS. 9 and 10 ). This could meanthat venetoclax renders LSCs more susceptible to cytolytic killing withcusatuzumab. However, as noted in Chou 2010 (Chou Cancer Res. (2010)Jan. 15;70(2):440-6, incorporated herein by reference), synergisticeffects between drugs are hard to predict, even in cases where there issome knowledge of the mechanism by which each individual drug acts.

The data presented in FIGS. 1-5 demonstrate that the Ven/Cusacombination exhibited a strong synergistic effect against AML cells,especially at high effect levels. The potent synergy was maintained forthe triple combination further including decitabine as a hypomethylatingagent.

This synergy is particularly advantageous since this indicates that,when the drugs are in combination, significantly lower concentrations ofeach drug can be used compared to the concentrations required to achievethe same effect as monotherapies.

Because the cell line experiments exhibited a strong synergistic effectof the venetoclax/cusatuzumab combination, the combination was tested onprimary AML LSCs. Primary LSCs provide a rigorous and more clinicallyrelevant assessment of potential therapeutic benefit, as these cellsdrive the aberrant proliferation characteristic of AML. The synergisticeffect of the Ven/Cusa combination therapy observed in the cell linestranslated to a potent reduction of primary AML leukemic stem cells(LSCs) from human patients (FIGS. 6-8 ). These data demonstrate that forall patient samples the combination therapy inhibited LSC colonyformation to an extent significantly greater than either therapy alone.The data appear to show a synergy between the components of the Ven/Cusacombination. (Due to the low numbers of primary cells available, it wasnot feasible to test the synergistic effect using the Chou-Talalaymethod).

When the effect of the cusatuzumab/venetoclax treatment on LSC functionwas analyzed in a more stringent way by serial re-plating experiments invitro, the impaired colony formation after combination treatmentobserved after the first plating was maintained during subsequent there-plating. This was the case even though cusatuzumab and venetoclaxwere not present in the re-plating, indicating an effective reduction ofLSCs and their proliferative potential.

The triplet combination cusatuzumab/venetoclax/decitabine reduced colonyand re-plating capacity of primary human LSCs to the same extent as thecusatuzumab/venetoclax combination treatment. It may be, therefore, thateffective treatment of AML can be achieved using the combination ofcusatuzumab and venetoclax without the need to include a HMA such asdecitabine, thereby reducing the exposure of the patient to toxictherapies.

1. A combination comprising: (i) an antibody or antigen binding fragmentthereof that binds to CD70; and (ii) a BCL-2 inhibitor, wherein theBCL-2 inhibitor is Compound (I)

or a pharmaceutically acceptable salt thereof.
 2. The combination ofclaim 1, wherein the antibody or antigen binding fragment thereof thatbinds to CD70 comprises a variable heavy chain domain (VH) and avariable light chain domain (VL) wherein the VH and VL domains comprisethe CDR sequences: HCDR3 comprising or consisting of SEQ ID NO: 3; HCDR2comprising or consisting of SEQ ID NO: 2; HCDR1 comprising or consistingof SEQ ID NO: 1; LCDR3 comprising or consisting of SEQ ID NO: 7; LCDR2comprising or consisting of SEQ ID NO: 6; and LCDR1 comprising orconsisting of SEQ ID NO:
 5. 3. The combination of claim 2, wherein theantibody or antigen binding fragment thereof that binds to CD70comprises a VH domain comprising an amino acid sequence at least 70%identical to SEQ ID NO: 4 and a VL domain comprising an amino acidsequence at least 70% identical to SEQ ID NO:
 8. 4. The combination ofclaim 3, wherein the antibody or antigen binding fragment thereof thatbinds to CD70 comprises a VH domain comprising the amino acid sequencerepresented by SEQ ID NO: 4 and a VL domain comprising the amino acidsequence represented by SEQ ID NO:
 8. 5. The combination of claim 1,wherein the antibody is an IgG.
 6. The combination of claim 1, whereinthe antibody has ADCC activity, CDC activity or ADCP activity.
 7. Thecombination of claim 1, wherein the antibody comprises a defucosylatedantibody domain.
 8. The combination of claim 1, wherein the antibody isARGX-110 (cusatuzumab).
 9. The combination of claim 1, wherein theantigen binding fragment is selected from the group consisting of: anantibody light chain variable domain (VL); an antibody heavy chainvariable domain (VH); a single chain antibody (scFv); a F(ab′)2fragment; a Fab fragment; an Fd fragment; an Fv fragment; a one-armed(monovalent) antibody; diabodies, triabodies, tetrabodies, and anyantigen binding fragment formed by combination, assembly or conjugationof such antigen binding fragments.
 10. The combination of claim 1,wherein the antibody or antigen binding fragment thereof and the BCL-2inhibitor are formulated as separate compositions.
 11. The combinationof claim 1, wherein the combination comprises at least one additionalanti-cancer agent.
 12. The combination of claim 11, wherein theanti-cancer agent is an agent for the treatment of acute myeloidleukemia (AML).
 13. The combination of claim 1, wherein the combinationadditionally comprises a hypomethylating agent.
 14. The combination ofclaim 13, wherein the hypomethylating agent is azacitidine.
 15. Thecombination of claim 13, wherein the hypomethylating agent isdecitabine.
 16. The combination of claim 1, wherein the CD70 antibody orantigen binding fragment thereof and the BCL-2 inhibitor are eachpresent in the combination in an amount sufficient to providesynergistic treatment when administered to a human subject with acutemyeloid leukemia.
 17. The combination of claim 1, wherein the CD70antibody or antigen binding fragment thereof and the BCL-2 inhibitor areeach present in the combination in an amount sufficient to providesynergistic cell killing when cultured with an AML cell line selectedfrom: NOMO-1, MOLM-13, NB4 and MV4-11.